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PREFACE

Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) has been routinely
used to evaluate and quantify the effectiveness of new drugs on tumor vascular characteristics
using gadolinium-DTPA as a contrast agent in MRI scans. It is a non-invasive tumor diagnostic
method, with which the perfusion in tissue can be visualized and can also provide important
functional information about tissue microvasculature. The most important requirement for DCEMRI is the need to compare results from different institutions. This work will provide us with
more reproducible DCE results by introducing a fixed T1(0) approach and by introducing new
DCE parameters to quantify cancer treatment efficacy. This work also enhanced the ability of
DCE-MRI as a non-invasive tool to decide the best treatment dose among a number of different
doses of the antiangiogenic drug, sunitinb.
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Chapter One
Introduction
1.1 Background and Project Motivation
Magnetic resonance imaging (MRI) was introduced to the medical field in the late 1970s,
and it is one of the most accurate, non-invasive and safe imaging modalities. It has been proven
to be one of the most promising methods to image human anatomy, and it functions with
reasonable resolution, which can reach the sub-millimeter level and give adequate structured,
detailed images (Haacke et al., 1999). MRI uses the magnetic properties of hydrogen protons in
tissues. The MRI signal depends on the density of hydrogen protons and their magnetic moment
interactions with the external magnetic field and the radio-frequency excitation (Bradley;
Faulkner, 1996). MRI has a number of advantages, such as high resolution 3D capability and
therefore the flexibility to produce different cross-sectional images in any plane (Hedley and
Yan, 1992). The most obvious and important advantages of MRI compared to other imaging
modalities is the absence of ionization radiation. This will spare the patients any additional risk
caused by such exposure and eventually allow regular and more frequent monitoring of lesions
inside the human brain, for example, compared to computed tomography (CT) or positron
emission tomography (PET) (Peters, 2000; Weiss et al., 2008). Clinical MRI has minimal risks
for imaging normal organs and tissues in human. Thus, MRI has proven to be a secure method to
explore the human body with highly detailed images.
MRI is a powerful means to non-invasively measure the vasculature and hemodynamic
parameters in tissues, using intrinsic endogenous or exogenous contrast agents. Many MRI
sequences have been developed to enhance image contrast, such as T1-weighted and T2weighted imaging, and/or to quantify tissue hemodynamic properties if the scan is repeated with
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time, such as diffusion and perfusion imaging. Perfusion imaging can be performed using two
different techniques: Dynamic Contrast Enhanced (DCE) MRI and Dynamic Susceptibility
Contrast (DSC) or so-called Perfusion Weighted Imaging (PWI). Both techniques (i.e., DCE and
DSC) use a bolus of contrast agent, gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA,
Magnevist, Berlex Laboratories, Wayne, NJ), that travels through the major vessels, then passes
through the capillaries and produces a transient signal enhancement (DCE) or signal loss due to
susceptibility effects (DSC) (Cha, 2004; Ludemann et al., 2009).
DCE-MRI has been used in many studies as a valuable tool to evaluate and quantify the
effectiveness of new drugs on the vasculature of tumors. It is a non-invasive tumor diagnostic
method, where the perfusion in tissue can be visualized by the flow of contrast agent and provide
important functional information about the tissue microvasculature, including tissue permeability
and blood volume (Galbraith et al., 2002). Increasing evidence suggests that microcirculatory
parameters derived from DCE-MRI can potentially be useful for tumor characterization and for
monitoring cancer therapy outcomes. However, no study discusses the use of DCE-MRI for
monitoring vascular changes induced by treatment in different sites of the organ or the tumor.
In general, three main methods to analyze data are used in DCE-MRI: histogram analysis,
extracting Ktrans, K ep and v e and parametric maps (Tofts and Kermode, 1991; Guo and Reddick,
2009). However, this quantification is difficult. DCE has many parameters that make it a very
complex technique, such as measuring the contrast agent concentration in the plasma or the socalled Arterial Input Function (AIF) and choosing the pharmacokinetic model (Galbraith et al.,
2002; Cutajar et al., 2009). Therefore, in this proposal, we will present new approaches to
overcome these limitations in DCE-MRI and enhance the quantification of tissue hemodynamic
parameters.
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The second chapter will briefly discuss cell cycle and tumor biology in order to
understand the hemodynamic differences between normal and tumor tissue. The third chapter
will explain the theory behind DCE-MRI, experiment requirements, DCE-MRI limitations and
sources of error. The fourth chapter is our published manuscript that uses DCE-MRI to select the
best treatment dose of the antiangiogenic drug sunitinib that affects the KCI-18 kidney tumors
with less impact on other healthy tissues (Neoplasia, 11, 910-920, 2009). Chapter five will
include our accepted manuscript that report the use of DCE-MRI to monitor the vascular changes
induced by pre-treatment with sunitinib to schedule the initiation of chemotherapy (Translational
Oncology Journal, in press 2010)
Chapter six will include our paper which we will submit to the Journal of Magnetic
Resonance Imaging. In this chapter we introduce new hemodynamic parameters that serve as a
measure to help study the treatment effect throughout the kidneys. And finally, chapter seven
will include our conclusion and future directions.

1.2 Project Aims:
The ability to assess blood perfusion and other tissue hemodynamic changes in tumors is
critical for the diagnosis and selection of proper treatment procedures. DCE-MRI has been
routinely used for tumor diagnosis by adding functional vascular information in addition to
anatomical detailed images. DCE-MRI is now a well-established diagnostic tool; however it has
some limitations. Numerous studies are investigating ways to enhance the ability of DCE-MRI
and to eliminate the sources of error. Therefore, in this project, we aim to first elucidate the
ability of DCE-MRI as a tool to select a dose of antiangiogenic drug to regularize the vasculature
of the tumor, and second, to develop new DCE parameters to clearly quantify the micro-vascular
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behavior of tumors and normal tissue in order to assess the treatment effect on tumors as well as
normal tissue.
After discussing DCE theory in the first two sections of chapter three, Section 3.3
introduces a new algorithm to quantify vascular changes using a fixed T1(0) instead of
calculating the original T1(0) for a region of interest. We hypothesized that using a fixed value
for T1(0) would eliminate most of the effects of the noise from the calculations of T1(t). Further,
it would increase the accuracy of the DCE-MRI method and would make it possible to utilize
data even when the multiple flip angle (FA) data used to find T1(0) was faulty.
Chapter four describes the use of DCE-MRI not only to study the effect of the
antiangiogenic drug, sunitinib, on the tumor and normal tissue but also as a tool to determine the
dose which causes regularization of the tumor vasculature with minimal impact on normal
healthy tissues. Chapter five uses DCE-MRI to monitor the vascular changes induced by pretreatment with sunitinib in KCI-18 kidney tumors to schedule the initiation of chemotherapy.
In chapter six, we discuss a number of new DCE parameters that we developed as well as
our hypothesis that DCE-MRI parametric maps have the potential to evaluate tissue physiology.
The treatment effect on both normal and tumor tissues can be described by these parametric
maps. We also introduced a new definition for full width at the half maximum (FWHM) from the
initial area under the curve (IAUC) histogram that has the potential to describe further the effect
of different treatment doses on tumor and normal tissues. We also hypothesized that the blood
volume fraction (λ) can be derived from the ratio of the concentration of the contrast agent in the
tissue to the concentration of the contrast agent of the blood vessel. This work will provide
clinicians with a new tool to enhance the ability to make clinical decisions regarding tumor
treatment.
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Chapter Two
Introduction to Kidney Anatomy and Tumor Biology
2.1 Kidney Anatomy and Physiology:
Kidneys are located in the abdominal cavity, one on each side of the spine. The main
function of the kidney is to maintain homeostasis or equilibrium between internal volume and
electrolyte status and that of the environment’s influences, diet and intake. It functions to maintain
our intra and extracellular fluid status at a constant despite the wide variety of daily fluid and
electrolyte intake.
The kidney has a bean-shaped structure. Figure 2.1 shows the kidney’s main region.
Kidneys are surrounded by tough fibrous tissue called the renal capsule. The outer, reddish region,
next to the capsule, is the renal cortex, which surrounds a region called the renal medulla. The
renal medulla consists of a series of renal pyramids, which contain straight tubular structures and
blood vessels. The cortex and medulla make up the parenchyma of the kidney. The calyx collects
urine from each pyramid. The urine flows in to the renal pelvis which located at the center of the
kidney.

Figure 2.1: Kidney’s main region: the renal
cortex, the renal medulla, the calyx and the
renal pelvis. The cortex and medulla make
up the parenchyma of the kidney. Once the
urine is formed, it is collected through the
calyx and flows to the renal pelvis which
located at the center of the kidney.
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The basic structural and functional unit of the kidney is the nephron which is located
between the kidney’s parenchyma (Figure 2.2). Nephrons are responsible for blood filtration and
waste extraction. Each nephron has a region called glomerulus which is a capillary tuft and where
the first filtration step occurs. The glomerulus is surrounded by the Bowman capsule and both,
the glomerulus and Bowman’s capsule, are located in the cortex of the kidney (Figure 2.2).
Each Bowman's capsule is a tiny filter. Blood containing waste substances, proteins,
sugars, etc., is forced to the kidneys by the pumping action of the heart. Under pressure, a
solution is driven out of the capillaries of the glomerulus through the walls of the capsule into its
hollow interior (Figure 2.2). The solution in the capsule is blood plasma minus the large
molecules. These molecules are big to pass through the capillary wall. From the capsule the fluid
passes along the tubule to the calyx till it reaches the renal pelvis.

Figure 2.2: The nephron is located in the
kidney’s parenchyma. Each nephron is
composed of an initial filtering component
(the renal corpuscle) and a tubule
specialized for reabsorption and secretion.
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Renal Blood Flow (RBF)
Kidneys receive the highest blood flow per gram of organ weight in the body via the renal
artery. Renal blood flow (RBF) is the fraction of the total cardiac output that flows through the
kidneys. The kidney is constantly fed by roughly 20% of the cardiac output or a renal fraction of
0.2. Thus, a very substantial portion of the total cardiac output flows through the kidneys. During
various stress conditions or disease, the renal fraction can vary considerably and be markedly
affected.

2.2 Cell Cycle and Tumor Biology
The term proliferative cell cycle includes a series of steps that occur and lead to cell division
and duplication. The cell cycle is a repeated process and has a series of regulatory checkpoints.
Over the last 25 years, the major progress of many studies was to identify the different factors
and molecules that regulate the cell cycle. Regulation of the cell cycle is very crucial to detect
and repair any genetic changes and to prevent uncontrolled cell division (Berges and Isaacs,
1993) (Udvardy, 1996; Pardee, 2006).
A dis-regulation of the cell cycle may lead to tumor formation. The word tumor
(medically: neoplasm) describes a disease that contains an abnormal growth of cells. It can be
either benign or malignant. Benign tumors are limited in size, are non-invasive and do not
metastasize. However, malignant tumors, which form cancer, show rapid growth, invade
adjacent tissues and spread to other locations. Cancer cells result from genetic changes during
cell division. Genetic changes vary from gaining or losing chromosomes to mutations affecting
the DNA nucleotide. Mutations happen in either oncogenes (genes that when mutated help to
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turn normal cells into cancer cells), or tumor suppressor genes that are able to transform the
normal cells into cancer cells (McAllister, 1965; Pardee, 2006).

2.2.1 Angiogenesis
Angiogenesis is the process of formation of new blood vessels from pre-existing vessels.
Under normal conditions, it is fundamental in any reproductive cycle such as restoring blood
flow to tissues after injury to enhance wound healing. However, in tumor cells, where rapid
proliferation is expected, the formation of new blood vessels is needed to provide the tumor with
nutrients and oxygen and allow tumor expansion (Kirsch et al., 2000).
Angiogenesis happens by activating the endothelial cells that lead to the formation of
new blood vessels. This process is regulated by angiogenesis stimulators and inhibitors which
binding to the tyrosine kinase receptors on the surface of endothelial cells (Neeman et al., 2007).
This stimulates the endothelial cell growth. The best-studied examples are the vascular
endothelial growth factors (VEGF) family (A, B, C and D) which bind to three different cell
specific VEGF receptors (VEGFR) with different affinity. Another example is the acidic and
basic fibroblast growth factors (FGF1 and FGF2) and their receptors. The functional
involvement of these growth factors and their receptors has been extensively studied (Kirsch et
al., 2000; Ashkenazi and Herbst, 2008). When the angiogenesis stimulating growth factors are
produced in excess of the inhibitors, then blood vessel growth takes place whereas when the
inhibitors are produced in excess, then angiogenesis halts.
In the early stages of tumor growth, the tumor can sustain itself through the passive
diffusion of nutrients and oxygen, but when the tumor volume exceeds the critical value of two
cubic millimeters, oxygen and nutrients have difficulty diffusing to the center of the tumor;
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hence, the tumor starts forming a new network of blood vessels to act as carriers for oxygen and
nutrients in order to sustain its rapid growth (Folkman, 2006). However, these blood vessels that
result from tumor angiogenesis are characterized as poorly differentiated and fragile compared to
normal mature blood vessels. These vessels are leaky due to the defective basement membrane
and lack of smooth muscle cell lining and are sometimes unable to match the rapid growth of
cancer cells, which results in areas of hypoxia and necrosis (Folkman, 2006). These structural
defects of tumor vessels cause increased interstitial tissue pressure, impaired blood supply, and
decreased oxygen supply in tumors compromising the delivery and efficacy of cytotoxic drugs
and radiotherapy (Jain, 2001).

2.2.2 Metastasis
The leakiness of tumor blood vessels could induce tumor metastasis. Metastasis is
defined as the transfer process of the tumor cells from the original tumor site to another site or a
different organ. The outcome of this process varies according to the host and the tumor
properties. Tumor cells can spread by three major routes. The first route involves direct
extension, in which a tumor growing in a body cavity releases cells or fragments that seed
serosal and/or mucosal surfaces to develop new growth. The second and third routes are via the
lymphatic and hematogenous compartments of the circulatory system. Both the thin walled
venules and the lymphatic channels show little resistance to tumor cell penetration. However, in
arteries the walls are more resistant because they contain more elastic and collagen fibers. After
infiltration to the blood stream, tumor cells undergo several interactions with platelets and other
blood cells until they reach the capillary beds (Fidler, 1978). Numerous studies (Zeidman and
Buss, 1952; Zeidman, 1957; Fisher and Fisher, 1967; Hagmar et al., 1984; Barbour and Gotley,
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2003) have demonstrated that the rate of tumor cells passing through capillary beds does not
depend on their size; rather, it depends on their ability to deform during transcapillary transport.
Once they reach the extravascular environment, they continue to proliferate.

2.3 Tumor Treatment:
Cancer can be treated with many methods such as surgery, antiangiogenic drugs,
chemotherapy and radiotherapy. This section will briefly discuss treatment methods where DCEMRI can be used to monitor the effects on cancer growth.

2.3.1 Surgery
Cancer surgery is used to remove cancerous growths from the human body. Depending on the
type of cancer and if it is localized to an organ with no metastasis, surgical removal might be
sufficient to cure cancer patients.

2.3.2 Antiangiogenesis drugs
Antiangiogenic drugs are designed to block the neovascularization process by preventing
VEGF from binding with the receptors on the surface of the endothelial cells and thus inhibit
formation of new blood vessels.
There are numerous angiogenesis inhibitors being tested in cancer patients. These
angiogenesis inhibitors are categorized based on their mechanism of action. One category of
angiogenesis inhibitors directly inhibits the growth of endothelial cells. Another category of the
angiogenesis inhibitors are those that act on steps in the angiogenesis signaling cascade
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(Cavallaro and Christofori, 2000; Zogakis and Libutti, 2001). For example, anti-VEGF
antibodies block the VEGF receptors from binding with the VEGF growth factor.

2.3.3 Chemotherapy
Chemotherapy is a general term that involves using chemicals drugs that attack the
genetic material inside the cell nucleus (DNA) and damage it. These chemicals invade the rapid
dividing cells and, hence, stop the cell division and replication. Several classes of
chemotherapeutic agents contain metal cations that are essential for their biological activities
such as zinc and calcium (Tobias and Whitehouse, 1976; Levin, 1998).

2.3.4 Radiotherapy
Radiation therapy uses ionizing radiation beams to target the malignant tumor cells and
stop its growth. The radiation beams are designed to react with the water inside the cell and
ionize it, creating a free radical that can damage the DNA of the dividing cell and prevent it from
growing or dividing. Tumor cells are unable to repair the DNA damage as they are not as
differentiated as normal cells. Hence, this DNA damage causes the tumor cell to die or have
slower proliferation (Mehta et al., 2000).
The radiation dose that is given to the patient will depend on the tumor location, type and
stage as well as many other factors such as combining the treatment with chemotherapy or
surgery and if the patient is treated with radiotherapy before or after the surgery.
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2.3.5 Cancer Treatment Decisions
After cancer diagnosis, the ideal treatment is to remove the cancer completely by surgery.
However, the choice of the treatment depends on many factors, such as the type of the cancer,
rate of progression, stage and location. When the tumor has metastasized, it is not feasible to use
surgery; chemotherapy or antiangiogenic drugs would be a better choice. Nevertheless,
chemotherapy and antiangiogenic drugs have their limitations. Chemotherapy is limited by its
toxicity to normal tissues, especially tissues with rapid growth. The problem with antiangiogenic
drugs is, beside targeting the normal vessels, they target only one of many factors that cause
angiogenesis in tumors while other factors continue stimulating the growth of new blood vessels
(Loiselle and Rockhill, 2009).
Radiotherapy can be used to treat most types of solid cancer. Radiotherapy treatment
dosage will depend on the radio-sensitivity of the cancer under treatment and the toxicity to
normal tissues/organs surrounding the tumor.
Combined treatments are also considered; some studies (Wolff et al., 2002; Ma and
Waxman, 2008; Loiselle and Rockhill, 2009) have reported better results by combining different
chemotherapy drugs, chemotherapy with radiotherapy or antiangiogenic drugs, or surgery with
any other modality.
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Chapter Three
Theory of Dynamic Contrast-Enhanced Magnetic Resonance Imaging
3.1 Magnetic Relaxation:
The source of the MRI signal is the hydrogen nuclei contained in the body’s water, which
counts for almost 60% of the human body. Hydrogen nuclei behave as small bar magnets pointed
in all directions with equal probability. However, when a subject is placed in an external
magnetic field, each hydrogen nucleus tends to align and possesses a magnetic moment. This
magnetization can be measured by an MRI scanner. The strength of the MR signal is
proportional to many factors such as hydrogen nucleus (i.e., water proton) density inside the
tissue scanned, strength of the magnet and the time required for magnetization that has been
disturbed by a radiofrequency (rf) pulse to re-align together, which is called the longitudinal
magnetization or spin lattice relaxation time T1. Magnetization is given by the following
equation:
t
− 

M z (t ) = M 0 ∗ 1 − e T1 



[3.1]

where M z represents magnetization parallel to the main magnet, M 0 is the original magnetization
and T1 is the spin lattice relaxation time (Haacke et al., 1999).
In living tissue there are many proteins and other macromolecules mixed with water.
These macromolecules can produce magnetic fields at the molecular level affecting proton
orientations which can shorten T1 values compared to pure water and result in image contrast.
Several paramagnetic ions, which have unpaired electrons, can be injected into the human body
to generate a powerful magnet that affects the relaxation time in order to produce image contrast
(LAUFFER, 1987; Caravan et al., 1999). Therefore, paramagnetic ions are used as MRI contrast
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agents (CA) because they change the relaxation time of water protons and enhance the image
contrast in T1-weighted images. Gadolinium is one example where it has seven unpaired
electrons in its outer orbit. These electrons can affect the water protons and alter their
orientations/directions, resulting in a shorter T1 value (Caravan et al., 1999). CA is typically
administered as a bolus of fluid via a catheter injection into a peripheral vein such as the
antecubital vein in humans and the tail vein in mice.

3.2 Theory of DCE-MRI:
DCE-MRI is based on running dynamic T1-weighted images through a volume of interest
and repeating it with time. Every time the whole volume of interest is imaged is called a time
point. The total number of time points is determined by the DCE protocol followed. T1-weighted
images are collected by applying short echo time (TE) and short repetition time (TR). Images
continue to be acquired before, during and after CA injection. Each time point is approximately
seven to eight seconds. The changes in the signal intensity of these images will depend on the
CA concentration which affects the T1 value of any tissue that has blood flow. In tumor tissue,
where the blood vessels leak into the surrounding extravascular space, the T1 value will be
shorter compared to the normal leak-free vessel tissues; hence, there will be higher signal
intensity in the tumor tissue compared to the normal tissue.
Figures 3.1 and 3.2 show a DCE-MRI example for imaging a mouse with an established
renal carcinoma in the right kidney. Signal enhancing took place after the CA was injected at
time point 10 (Figure 3.1). More signal enhancement can be seen in the mouse’s normal kidneys
that have more blood flow compared to other surrounding tissues with less blood flow. For data
analysis, the full kidney was selected as a region on interest (ROI) for the kidney tumor (KT)
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(blue contour on left of T1 image) and the contralateral left normal kidney (NK) (red contour on
right of T1 image) as shown in Figure 3.2.

S(t) graphs
Figure 3.1: Signal enhancement after
contrast agent injection. Contrast agent
was injected at time point 10. DCE image
are then acquired for 20 more time points.
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Figure 3.2: DCE-MRI example of mouse kidneys. A) Dynamic image pre-contrast, B)
Dynamic image post-contrast, C) Subtracted Image, D) Flip Angle 5 Image, E) Flip Angle
30 Image and F) T1 image. Images A-F are used when processing a case wit DCE-MRI.
Note the signal enhancement on the right kidneys with established tumor (blue contour)
compared to the left normal kidneys (pink contour).
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To perform DCE analysis we need to acquire T1-weighted images with high temporal
resolution, extract the original T1 value for the tissue before CA injection (i.e. T1(0)) and define
a method to extract tissue hemodynamic parameters. Dynamic DCE images are collected using a
sequence called fast low angle short (FLASH). A FLASH sequence is a fast gradient echo
imaging technique where the repetition times (TRs) for the data acquisition are very small
compared to the T1 relaxation times of the tissues being imaged combined with a low flip angle
rf pulse (Cron et al., 1999). Because of such short TR value, there will not be enough time for
longitudinal magnetization to grow back to its equilibrium value M0, nor for the transverse
magnetization to completely decay between each data acquisition step. Transverse magnetization
might lead to coherent signal buildup; therefore, in a FLASH sequence it is purposefully
destroyed or ‘spoiled’ before each subsequent acquisition step.
The changes in the DCE signal with time, S(t), for a given flip angle, can be obtained
from the following FLASH equation:
S θ (t ) =

ρ 0 sin θ (1 −e −TR / T 1(t ) ) −TE / T 2
∗e
(1 − e −TR / T 1( t ) cos θ )

*

[3.2]

where ρ 0 is the spin density, θ is the flip angle, T2 is the transverse relaxation time, TR is the
repetition time and TE is the echo time.
The changes in CA concentration with time can be calculated from the following
equation:
C (t ) =

1  1
1 
*
−
a  T 1(t ) T 1(0) 

[3.3]

where “ a ” is the proportionality constant referred to as the longitudinal or T1 relaxtivity with
units of (mM)-1s-1, and it is a property specific to the composition of the CA. T1(0) is the tissue
T1 value prior to CA injection, and T1(t) represents T1 changes with time. C(t) calculation needs
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both the T1(0) value and T1(t) function which will be explained in the following two sections
(Roberts et al., 2006; Haacke et al., 2007).

3.2.1 T1(0) calculations:
In order to calculate the initial T1(0) for a region of interest, two flip angle images are
collected with θ 1 and θ 2 respectively prior to CA injection. The signal from these two sequences
will equal
S θ1 (0) =

ρ 0 sin θ1 (1 −e −TR / T 1( 0) )
(1 − e −TR / T 1( 0 ) cos θ1 )

and S θ 2 (0) =

ρ 0 sin θ 2 (1 −e −TR / T 1( 0) )
(1 − e −TR / T 1( 0 ) cosθ 2)

[3.4]

[3.5]

Given that TR, θ 1 and θ 2 are known, re-arranging the above equations in the form of
( y = mx + c ) we have

Sθ 1 (0)
S (0) −TR / T 1( 0 )
= ρ 0 (1 −e −TR / T 1( 0 ) ) + θ 1
e
Sinθ1
Tanθ1
Sθ 2 (0)
S (0) −TR / T 1( 0 )
= ρ 0 (1 −e −TR / T 1( 0 ) ) + θ 2
e
Sinθ 2
Tanθ 2
The slope m of the above equations is equivalent to e −TR / T 1( 0 ) ; plotting these two points
((

Sθ 1 (t ) Sθ 1 (t )
S (t ) S (t )
,
), ( θ 2 , θ 2 )) and finding the slope of the line connecting them gives us
Tanθ1 Sinθ1
Tanθ 2 Sinθ 2

the value of T1(0) ( see Figure 3.3).
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Figure 3.3: T1(0) calculations. Each point
represents the ratio between the signal to
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For more than two flip angles, we calculate (

( Sθ 1 (t ) , S θ 1 (t ) ),( θ 2 , S θ 2 (t ) )) is equal to
Tanθ 2 Sinθ 2
Tanθ1 Sinθ 1
e −TR / T 1( 0 ) . According to a given TR; T1(0)
can be calculated. For more than two flip
angles, linear regression will be used to
find the slope.

S θ (t ) S θ (t )
,
) for each angle and use linear
Sinθ tan θ

regression to find the slope and, accordingly, the T1(0) value, where for y = mx + c
m=

n∑ ( xy ) − ∑ x ∑ y
n∑ ( x 2 ) − (∑ x ) 2

and
c=

∑ y − m∑ x
n
However, there are multiple problems with this approach. First, the extraction of T1 is a

noisy procedure. Second, the noise manifests itself as both a broadening of the histogram of data
in the IAUC. Third, rf profiles in either 2D or 3D affect the resultant T1 calculation. Therefore, a
new algorithm using a fixed T1(0) value has been proposed in our paper published in Magnetic
Resonance in Medicine in 2007 ( Section 3.3).

19
3.2.2 T1(t) calculations:
For a given TR, T1(t) can be calculated from rearranging equation # 3.2 as a ratio between the
signal at any time “t” to the initial signal before CA injection as in the following equation:
(1 − e −TR / T 1(t ) )
s (t )
(1 − e −TR / T 1( 0 ) cos θ )
=
*
s (0) (1 − e −TR / T 1(t ) cos θ )
(1 − e −TR / T 1( 0 ) )
Simplifying the equation and assuming y=
We get T1(t)=

(1 − e −TR / T 1( 0 ) cos θ )
s (t )
and x=
(1 − e −TR / T 1( 0 ) )
s (0)

− TR


x− y
ln 

 x − y * cos θ 

[3.6]

Figure 3.4-A shows the resulting T1(t) curve and its variation after CA injection. The C(t) value
can be found by substituting the T1(t) values and T1(0) in equation # 3.3 ( see Figure 3.4-B).
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Figure 3.4: A) T1(t) curve, which represents the T1 value for the region of interest (ROI) with
time. Notice after CA injection, the T1 value shortens. B) The C(t) curve, which represents the
CA concentration in the selected ROI.
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3.2.3 Model free DCE quantification
After calculating C(t) for each fixed T1(0), the initial area under the curve (IAUC) is
calculated from the following equation:
t2

IAUC = ∑ C (t )∆t

[3.7]

t1

For each pixel, the next step in the process is to calculate the cumulative initial area under
the curve (CIAUC), which represent the cumulative number of pixels counted within an ROI that
corresponds to a given contrast uptake (xi) and normalize them to the total number of pixels
(where xi = IAUC(i) for (1 ≤ i ≤ N bins) in a given ROI) and n(xi) is the number of pixels with a
value in that bin:
m

CIAUC (m) =

∑ n( x )
i =1
N

i

∑ n( x )
i =1

[3.8]

i

where N represents the last bin or maximum IAUC.
We define the R50 value as that value of xi where CIAUC(m) = 50% (the median value
of the histogram) (Roberts et al., 2006). Although this value serves as the reference for the predrug treatment, when a fixed T1 is used we define instead the NR50, which is a normalized
version of the R50 as defined below:
NR50 = ( R50 pre − R50 post ) / R50 pre

[3.9]

where R50 pre represents the R50 value before drug treatment and R50 post represents the R50
value after drug treatment.
If the drug successfully reduces the vascular content, the CA uptake will be reduced.
Therefore, the R50 will shift to the left (to a smaller value) and the NR50 will be a positive
number between 0 and unity. If the tumor has not responded and/or the vascularity has increased,
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the NR50 will be zero or negative. Figures 3.5 and 3.6 show the IAUC and CIAUC graphs
respectively.

Iauc graphs/16 time points
% number of pixels

6
5
4
3
2
1
0
0

2

4
6
Iauc
in mmol-sec

8

10

Figure 3.5: IAUC histogram, which represents the histogram of the number of pixels as a
function of CA uptake in mmol-sec.
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Figure 3.6: Cumulative distribution (CIAUC) of CA uptake.
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3.3 New Algorithm for Quantifying Vascular Changes in Dynamic Contrast-Enhanced
MRI Independent of Absolute T 1 Values (Haacke et al., 2007)
We introduce here a novel method to avoid the need to find absolute T1 values and
dramatically improve the signal-to-noise ratio (SNR) in processed DCE-MRI data. We
hypothesized that using a fixed value for T1(0) would eliminate most of the effects of the noise
from the calculations of T1(t). Further, it would increase the accuracy of the DCE-MRI method
and would make it possible to utilize data even when the multi flip angle (FA) data used to find
T1(0) is faulty.
To avoid the effects of noise from the multiple FA images in calculating T1(0), we
proposed to force all T1(0) values from the selected region of interest (ROI) to be equal to a
fixed value close to that of the actual T1 value of the tissue. This approach should dramatically
enhance the SNR of the calculations and make the method much more robust in a clinical setting.

3.3.1 Materials and Methods:
We test our hypothesis using simulated data. We started by creating a series of images
with a range of T1 values (250 ms, 500 ms, 1000 ms and 1500 ms) at two different FA of 5º and
13º. Then a series of eight DCE images with known values of C(t) was generated.
C (t ) = C 0 (1 − e − at )e − bt

[3.10]

T1(t) is found for T1(0) starting values of 250 ms up to 2000 ms in increments of 250 ms. The
values of TR = 3.8 ms and ρ o (to mimic real human data) were inserted into Eq. [1]. Two noise
values were added (Gaussian noise determined with the Box-Mueller method (16)) to the FA 5°
and 13° images (SD=40 a.u., and SD =80 a.u. with mean =0). With these datasets the effects of
noise were simulated for T1, IAUC, CIAUC, and R50.
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The 50% mark (R50) of the CIAUC was used to represent a vascular measure for each of
the two experimental conditions of pre (a=1/4, large values of a represent rapid uptake) and post
(a=1/8, small values of a represent slow uptake) CA injection. The two R50 values pre drug
treatment and post drug treatment were used to quantify the normalized change in contrast
uptake (presumably due to vascular changes in the tissue). The normalized NR50 is calculated
from NR50 = (R50 pre – R50 post ) / R50 pre , and this value is examined with a fixed T1(0) ranging
from 250 to 2000 ms in 250 ms increments. If NR50 remains constant independent of T1(0), then
the method can be considered a robust technique which can be used for all tissues in the body.

Estimating T1 from Simulated Data
The simulated data were then analyzed as discussed above to find T1(t) in the noisy data, extract
C(t), find IAUC, and finally find the CIAUC. For the conventional approach, two FAs of 5° and
13° are used to obtain T1(0). Alternatively, we chose instead to fix T1(0) to one of 750 ms, 1000
ms, 1250 ms, 1500 ms, 1750 ms, or 2000 ms. All simulations are performed for a single input T1
representing a homogeneous tumor.

3.3.2 Results
The effect of noise on T1(0) is demonstrated in Figure 3.7 for various T1(0) values and
SNR. Clearly, the noise plays a key role in broadening the T1(0) estimates because there is noise
present in the multi-FA images (here we used 2 FAs, 5° and 13°) and noise present in the
dynamic images. The larger the noise value, the broader the distributions become and the more
skewed they become toward higher T1(0) values. Practically, such a large spread in T1(0) will
further distort the CIAUC if the analysis method discards what look like noise points or points
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which have a T1 that is too high. Therefore, the estimates for the calculated values are a
conservative estimate as to how inaccurate they can become.

Figure 3.7: Histogram of T1(0) calculated
for a noise SD = 40 a.u. using T1(0) equal
250 ms, 500 ms, and 1000 ms. Note the
asymmetry of the T1 values about the
mode with a large tail to the right toward
higher T1. This skewness leads to an
overestimate (bias) of the estimated mean
value for T1.

Using a fixed T1(0), the spread in T1(t) is dramatically narrowed, leading to better
estimates of the IAUC (Figure 3.8) and CIAUC (Figure 3.9). The behavior of the bad points is
clearly observed with a spike at CIAUC at zero in Figure 3.9-b when T1act is 1000 ms and the
noise level is SD = 80 a.u. The same figure also shows a normalized curve for the same values
which clearly discards the counting of the bad points in the calculation of the CIAUC values. As
expected, when T1(0) fixed is greater than the original T1(0), C(t) is reduced and the IAUC
shifts to the left. We also observe that the IAUC narrows relative to the ideal values.
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Figure 3.8. Histograms of the number of pixels as a function of contrast uptake in mMs.
Simulated data were created with T1(0) fixed to 1000 ms and calculated for a T1(0)act of 500
ms, with SD=40 a.u., SD=80 a.u., c o = 2 and the exponential constant value of a = 1/4. Note the
shift to the left of the IAUC for T1(0) fixed to 1000 ms and the spread of the IAUC for growing
noise levels. The spread of the IAUC is significant when the calculated approach was used. This
demonstrates the robustness to noise of the T1(0) fixed method.
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Figure 3.9. Cumulative distribution functions as a function of contrast uptake in mM.s.
Simulated data were created with T1(0) fixed to 1000 ms (a), and calculated (b), with no noise
and levels of noise SD=40 a.u., SD =80 a.u., c o = 2, and the exponential constant value of a=1/4.
T1act=250 ms, 500 ms and 1000 ms. Observe in (a) that the 50% CIAUC mark crosses for the
T1(0) fixed, while it deviates from the 50% of the total number of pixels when being calculated
from the FLASH equation (b). Only one no noise plot is shown since they all overlap each other
(dotted line). Note that the CIAUC plots are broader for the calculated T1(0) case. The 50%
CIAUC values are shown in the table to explain the above description. (*This value is calculated
from the zero-removed dataset.)
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Since the goal of the DCE experiments is to determine the percentage of vascular change,
it would appear that the use of a fixed T1(0) method may be suitable to draw the correct
conclusions despite the fact that the calculated C(t) will not be physiological. The only important
element of this calculation is the correct prediction of the tissue response to vascular change
from the drug treatment.
To test this hypothesis we used the two different models of CA uptake described above.
Table 3.1 shows the ratio of the IAUC value at its peak over the full width at half magnitude
(FWHM) for different values of tissue T1(0) and fixed T1(0). This measure shows that although
the IAUC histogram may shift to the left, the FWHM narrows in proportion to the shift, making
the ability to measure R50, and hence NR50, just as sensitive to the measure that would have
taken place had the exact values of T1(0) been used. In fact, it can be seen that using a larger
T1(0) often increases this ratio, which means that it remains a very sensitive means by which to
judge the NR50 even for larger T1(0) values than the actual T1(0).
The NR50 variations for the different choices of fixed T1(0) in the pre/post-tumor
treatment model described earlier are shown in Table 3.2. When the correct value of T1(0) is
used, the NR50 in this model is 0.34. When a higher value is used this drops to 15% to 20% less
than 0.34 or between 0.27 and 0.30. The key element here is that these values are close to 30%
and do not vary wildly. The standard error of these measurements is consistently 3% (6%) for
fixed T1(0) and 6% (12%) or more for the calculated data with an SD of 40 a.u. (80 a.u.) when
evaluated with a fixed T1(0) of 1000 ms.
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Table 3.1: The IAUC value at the peak of the histogram over the Full Width at Half Magnitude
(FWHM) for varying values of tissue T1(0) (referred to here as T1(0)act) and the forced fixed
value of T1(0) (the value of T1(0) is given in ms).

T1(0)act,T1(0)fixed
250, 250
250, 500
250, 750
250, 1000
250, 1250
250, 1500
250, 1750
250, 2000
500, 500
500, 750
500, 1000
500, 1250
500, 1500
500, 1750
500, 2000
1000, 1000
1000, 1250
1000, 1500
1000, 1750
1000, 2000
1500, 1250
1500, 1500
1500, 1750
1500, 2000

IAUC(peak value)/FWHM
a=1/4
a=1/8
SD=40 a.u. SD=80 a.u. SD=40 a.u. SD=80 a.u.
2.28
1.17
2.25
0.90
3.64
1.30
2.48
1.21
4.17
1.17
2.33
1.06
4.77
1.46
2.36
1.64
3.92
1.27
2.13
1.20
4.00
1.32
3.11
1.13
3.76
1.44
2.94
1.30
3.93
1.45
3.15
1.37
1.36
1.24
1.48
1.06
2.57
1.12
1.94
1.14
3.03
1.52
2.39
1.37
3.10
1.13
2.46
1.31
3.11
1.17
2.39
1.31
3.20
1.24
3.25
1.05
2.91
1.33
3.45
1.39
1.07
0.84
1.00
1.09
1.01
0.81
1.42
1.35
1.45
0.81
1.49
1.21
1.78
0.86
1.90
1.04
1.68
0.81
1.84
1.17
0.94
0.82
0.93
0.82
0.88
0.84
1.26
0.84
0.87
0.72
1.26
0.83
0.96
0.84
1.26
0.82
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Table 3.2: The NR50 = [R50 (a=1/4) - R50 (a=1/8)] / R50 (a=1/4), for no noise, and noise levels
of SD= 40 a.u. and SD= 80 a.u.. From Table 1, the SNR ranges from 5:1 to 37:1 depending on
the T1 of the tissue. The table below exemplifies the fact that lower T1 values lead to higher
SNR and vice versa.

T1(0) (ms) fixed
T1(0)act (ms)
250
No

500

Noise

1000

250

500

750

1000 1250 1500 1750 2000

0.34 0.29 0.27

0.27

0.27

0.26

0.27

0.26 0.34

0.34 0.30

0.28

0.27

0.26

0.26

0.26 0.34

0.34

0.31

0.29

0.28

0.28 0.34

0.34

0.32

0.30 0.34

1500
250
SD=40

500

a.u.

1000

0.34 0.29 0.28

0.27

0.27

0.26

0.26

0.26 0.35

0.34 0.29

0.28

0.27

0.26

0.25

0.25 0.34

0.34

0.31

0.29

0.28

0.28 0.35

0.34

0.32

0.30 0.35

1500
250
SD=80

500

a.u.

1000

cal

0.34 0.29 0.28

0.27

0.27

0.27

0.26

0.26 0.34

0.36 0.31

0.30

0.29

0.28

0.28

0.27 0.30

0.33

0.31

0.29

0.28

0.27 0.31

0.31

0.30

0.29 0.16

1500

3.3.3 Discussion and Conclusion
Robustness of the Fixed T1 Method
Current DCE analysis requires the calculation of T1(0) and subsequently T1(t). Noise in
the experiments leads to very poor behavior of the extracted C(t) values and the IAUC. This
sensitivity to T1(0) and the effect of the noise on the spread of T1(0) estimates can be effectively
eliminated by forcing T1(0) to a fixed value, preferably greater than the actual T1(0) of the tissue
under investigation. The results indicate that the IAUC became much more stable. The spread in
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T1 and therefore in the IAUC in the noisy cases was so broad that T1 values ranged from almost
zero to 3000 ms. This broad spread was dramatically reduced using the fixed T1(0) approach.
Clearly, any programmatic issues dealing with noise and cutoff issues would bias the distribution
and cause much worse shifts than what was shown in the simulated results. These problems do
not occur when using the fixed T1(0) approach. (A stable IAUC can be very important if one is
evaluating the histograms for shifts rather than the CIAUC. If this approach is taken, issues
related to noise spikes and erroneous shifts in the CIAUC can be avoided.)
Through our simulations we observed that a single T1(0) can be used for the entire
image. This is not necessary, though, as each tissue could in theory have its own T1(0) fixed in
the ROI analysis. Performing this operation on both pre- and post- drug treatment cases should
make it possible to obtain a reliable estimate for the relative changes shown by the R50 changes
of the tissue. This also has the advantage that if data at different FAs are corrupt or not collected,
the DCE acquisition still has value. Using the relative changes in R50 via NR50 may also reduce
any inherent errors in calculating T1 that come from variations in T2* caused by the CA itself
(17).
By using a fixed T1(0), we are forced to consider relative changes in R50 since we no
longer have absolute T1(t) information. This is accomplished using the NR50. Ideally, the NR50
would prove to be identical between the two methods, and this is not far from the case, as shown
in Table 3.2 The ideal changes expected in the two different models of C(t) uptake should have
an NR50 equal to 0.34 (or a 34% shift to the left of the R50). In practice, with the fixed T1(0)
approach they are closer to 0.27 to 0.30. We evaluated a number of practical cases and found that
the error in tumor R50 variability can be as high as 0.17; thus, we chose 0.34 as a 2 SD model.
Therefore, to err on the safe side, it would be wise to keep 0.34 as the P = 0.025 cutoff point
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above which we could consider the effect of a vascular shift to be real. This choice is in
agreement with a very recent publication (Roberts et al., 2006) and earlier works (Galbraith et
al., 2002; Dale et al., 2003) suggesting that 30% is a adequate cutoff in a clinical environment.
Our results show, however, that the actual white noise contribution is only 6–12% with SNR
available on 1.5T systems today. Therefore, this 30% value is quite conservative and likely to be
quite safe in drawing conclusions about actual changes in the NR50.
In the simulations, we used a specific set of T1 values as reasonable estimates of the
clinical situation. Measuring the T1(0) value of the muscle, liver, and tumor in a series of 22
DCE-MRI experiments, we found that T1(0) for the muscle was 855 ms (SD = 180 ms), T1(0)
for the liver was 680 ms (SD = 150 ms), and T1(0) for the tumor was 1400 ms (SD = 230 ms).
Therefore, we chose to use the rather general values of 500 ms, 1000 ms, 1500 ms, and 2000 ms
to cover the spectrum of values for tissue and tumors.
We also evaluated the effect of bin size in estimating the IAUC and the CIAUC as well
as the R50 and NR50. For values of 0.01–0.05 mM.s, we obtained the same NR50 values to
within 0.01, but large effects were observed when the bin size was 0.1 or higher.
Finally, tissue T1(0) heterogeneity will affect both the fixed and calculated approaches.
To investigate this we simulated a variety of heterogeneous models with varying T1(0) from
250–1500 ms and found that the NR50 behaves in a similar fashion to the homogeneous case
presented here.
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3.4 DCE-MRI Requirements:
To conduct a successful DCE-MRI experiment several requirements should be met when
designing an experimental protocol such as the following: high temporal and spatial resolution,
volume coverage, image signal to noise ratio (SNR), access to arterial input function (AIF), and
suitable contrast agent (CA) dosage.

3.4.1 High temporal and spatial resolution:
Vascular heterogeneity within the tumor can affect the temporal and spatial resolution
required of DCE-MRI in several ways. High temporal resolution is very important to decrease
the error in estimating DCE parameters. One impact is the need to sample the entire volume to
take full advantage of this non-invasive method. If the study aims to characterize the tumor,
failure to sample the entire tumor could result in sampling errors of the type associated with
invasive assays, i.e. the region sampled is not representative of the entire tumor. Tumor
simulations suggest to sample the AIF every 1 sec and tissue signal every 4 sec in order to keep
the error in model parameters below 10%. This is due to the highly permeable and highly
vasculature tumor (Henderson et al., 1998).
High spatial resolution is needed to overcome problems such as partial volume effect
which might lead to masking important pathology details (Furman-Haran et al., 2001). It should
be in the order of standard structural MRI data acquisitions.

3.4.2 Volume coverage and image SNR:
For tumor volume acquisition, it is very important to cover the whole tumor volume,
especially when a comparison study is planned (Zhu et al., 2000). However, the imaging
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protocol should optimize the above mentioned requirements (i.e., high temporal and spatial
resolution and adequate volume coverage) with an acceptable signal-to-noise ratio (SNR). Image
SNR can affect the quality of parametric maps that can be produced from the original DCE
images.

3.4.3. Arterial Input Function (AIF):
Upon reviewing the literature, we encountered three main approaches to measure AIF: by
inserting an arterial catheter into the subject and take blood samples to measure it, by assuming
AIF is the same for all subjects (Tofts and Kermode, 1991), or by obtaining AIF from DCE data.
Nevertheless, these approaches have many problems, such as being invasive, having poor
temporal resolution, being relative ambiguous concerning the actual time, influencing of both
inter and intra subject variations in AIF, and, finally, requiring the presence of a large vessel
within the FOV as well as the need to devoid partial volume or flow effect (Parker et al., 1996;
Cha, 2004). These problems make AIF very difficult to calculate.

3.4.4. Contrast agent dose and administration time:
In DCE-MRI a clinical protocol demonstrates that both the dose and bolus administration
is needed. Many studies (Hulka et al., 1995; Henderson et al., 1998) demonstrate that shorter
injection of the CA is desirable. Shorter injection time can help reduce the effects of noise
modeling errors. However, we need to acquire high temporal resolution to cope with these
values.
Higher CA dosing can enhance the signal intensity in T1-weighted images up to some
limit. Some sequences suffer from high susceptibility sensitivity, which might lead to a drop in
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signal intensity as a result from high CA concentration in the arteries in the region of interest
(Tofts, 1996).

3.5 DCE-MRI Artifacts:
As we mentioned earlier the main source of error in DCE experiments is estimating the
T1(0) value (Parkera et al., 2000). Usually two points are collected to calculate T1(0) which has
more exponential components than liner components. This explains our use of the fixed T1(0)
approach (Haacke et al., 2007). Another complication in DCE is to choose a model that describes
the behavior of the CA uptake and clearance by the tumor. It is still not clear if complicated yet
well-characterized models are more or less useful in understanding and assessing the treatment
results compared to simple yet more noisy models. Other imaging artifacts also affect the DCE
results such as patient motion, errors in CA relaxivity and water exchange rates. Further, CA
increase the susceptibility effect and changed the T2* value; hence, this will result in inaccurate
T1(t) measurements (Roberts, 1997).
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4.1 Abstract
To investigate further the antiangiogenic potential of sunitinib for renal cell carcinoma
(RCC) treatment, its effects on tumor vasculature were monitored by dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) using an orthotopic KCI-18 model of human RCC
xenografts in nude mice. Tumor-bearing mice were treated with various doses of sunitinib, and
vascular changes were assessed by DCE-MRI and histologic studies. Sunitinib induced dose
dependent vascular changes, which were observed both in kidney tumors and in normal kidneys
by DCE-MRI. A dosage of 10 mg/kg per day caused mild changes in Gd uptake and clearance
kinetics in kidney tumors. A dosage of 40 mg/kg per day induced increased vascular tumor
permeability with Gd retention, probably resulting from the destruction of tumor vasculature, and
also caused vascular alterations of normal vessels. However, sunitinib at 20 mg/kg per day
caused increased tumor perfusion and decreased vascular permeability associated with thinning
and regularization of tumor vessels while mildly affecting normal vessels as confirmed by
histologic diagnosis. Alterations in tumor vasculature resulted in a significant inhibition of KCI18 RCC tumor growth at sunitinib dosages of 20 and 40 mg/kg per day. Sunitinib also exerted a
direct cytotoxic effect in KCI-18 cells in vitro. KCI-18 cells and tumors expressed vascular
endothelial growth factor receptor 2 and platelet-derived growth factor receptor β molecular
targets of sunitinib that were modulated by the drug treatment. These data suggest that a sunitinib
dosage of 20 mg/kg per day, which inhibits RCC tumor growth and regularizes tumor vessels
with milder effects on normal vessels, could be used to improve blood flow for combination with
chemotherapy. These studies emphasize the clinical potential of DCE-MRI in selecting the dose
and schedule of antiangiogenic compounds.
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4.2 Introduction
Renal cell carcinoma (RCC) incidence has increased in recent years with approximately
54,390 new cases each year in the United States. The disease is responsible for an estimated
13,010 deaths each year (Jemal et al., 2008). Nearly half of the patients present with localized
disease that can be treated by surgical removal (Haas and Hillman, 1996). However, one third of
the patients have metastatic disease at first presentation, and 20%to 30%of the patients treated
for localized RCC subsequently develop metastatic disease that frequently involves the lungs
(Haas and Hillman, 1996). The median survival of patients with metastatic RCC ranged from8 to
11months (Haas and Hillman, 1996; Flanigan et al., 2001). The treatment of metastatic RCC
remains a significant challenge, but recent developments in antiangiogenic therapy have
improved targeting these highly vascularized tumors.
The vascular endothelial growth factor (VEGF), produced by tumor cells and associated
stromal cells, is a key growth factor in the angiogenic process, which promotes the proliferation,
migration, and invasion of endothelial cells and plays a role in vascular permeability. Targeting
the tumor vasculature with antiangiogenic therapy has been shown to suppress the growth of
established tumors in mice, leading to several clinical trials with different angiogenesis inhibitors
(Kerbel and Folkman, 2002). Numerous antiangiogenic compounds recently developed include
anti-VEGF antibodies and inhibitors of receptor tyrosine kinases (RTKs). The drug sunitinib
(SU11248 or Sutent) is a small-molecule RTK inhibitor that has demonstrated antitumor and
antiangiogenic activities in mouse xenograft models. Sunitinib targets and inhibits signaling of
several RTKs including platelet-derived growth factor receptor (PDGFR), VEGF receptor
(VEGFR), c-kit protooncogene, and FMS-like tyrosine kinase 3 (Abrams et al., 2003; Murray et
al., 2003; O'Farrell et al., 2003; Xu et al., 2005). Sunitinib exhibits direct antitumor activity by
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inhibiting RTKs that are expressed by cancer cells and are involved in signaling for cancer cell
proliferation. Sunitinib also exhibits antiangiogenic activity by inhibition of signaling through
VEGFR-2 and PDGFR-β RTKs expressed on endothelial cells or stromal cells. Initial clinical
trials with sunitinib for metastatic RCC showed significant responses in multiple metastatic sites
and in primary tumors resulting in 40%partial response rate with a median time to progression of
8.7 months (Motzer et al., 2006). These studies justified approval of sunitinib by the FDA in
January 2006 for RCC treatment. In a phase 3 multinational study of 750 patients with metastatic
RCC, randomized to sunitinib or interferon α, the response rate to sunitinib was 31%, with
median progression-free survival (PFS) of 11.7 months and a median survival of 28 months
(Motzer et al., 2007). A recent update of this trial documented an objective response rate of 47%
with 11 months of median PFS for sunitinib versus 12% objective response rate and 5 months of
PFS for interferon α (Kollmannsberger et al., 2007). Although the results with sunitinib therapy
are impressive, long-term control of the disease is still not achieved. In addition, several trials
documented adverse effects of cardiotoxicity in some of the patients, probably as a result of
alterations to normal vasculature (Jain, 2005; Chu et al., 2007; Schmidinger et al., 2008; Telli et
al., 2008). Therefore, further investigations with sunitinib dose adjustments are warranted to
decrease the impact on vital organs such as the heart and the kidney.
The goal of our study was to investigate the effect of lower and potentially less toxic
doses of sunitinib on tumor vasculature to establish the conditions for combination therapies to
determine whether a combined strategy could maintain and improve efficacy. Disruption of the
tumor vasculature to deprive tumor cells from nutrients by sunitinib, given in conjunction with
cytotoxic therapies, could be more effective in preventing progression of metastatic RCC.
However, this approach could be a paradox given that complete destruction of tumor vasculature
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could compromise the efficacy of chemotherapy or radiotherapy because both depend on blood
flow to the tumor for delivering oxygen and drugs (Jain, 2001). To improve the blood flow in
tumors, the concept of “normalization” of tumor vasculature is based on the regularization of
tumor vessels by pruning or destroying immature and inefficient blood vessels through
elimination of excess endothelial cells, and it has shown promise for combination therapies
(Browder et al., 2000; Lee et al., 2000; Wildiers et al., 2003). The process of tumor angiogenesis
involves proliferation of abnormal vessels that are enlarged, disorganized, and leaky due to the
defective basement membrane. These structural defects of tumor vessels cause increased
interstitial tissue pressure, impaired blood supply, and decreased oxygen supply in tumors
compromising the delivery and efficacy of cytotoxic drugs and radiotherapy (Jain, 2001). The
challenge is to develop imaging technologies that monitor early vascular changes and induction
of tumor vasculature normalization by antiangiogenic drugs for scheduling cytotoxic therapy.
We selected to use dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
to investigate the effect of sunitinib therapy on RCC tumor vasculature using a preclinical
papillary RCC murine model. DCE-MRI is a noninvasive approach, currently used in humans
that can detect early changes in the tumor induced by antiangiogenic therapy as reported in
human studies (Checkley et al., 2003; Hahn et al., 2008) and in preclinical animal models
(Marzola et al., 2005). This method measures a combination of tumor perfusion and vessel
permeability and allows the detection of changes in tumor vascularity, which occur at a much
earlier stage in the treatment of tumors with antiangiogenic drugs than does shrinkage of tumor
mass (Checkley et al., 2003; Hahn et al., 2008). Contrast agents typically consist of gadolinium
(Gd)-based chelates with paramagnetic properties that are used to enhance signal from the tissue
in clinical MRI. The contrast agent, injected intravenously, enters the extravascular extracellular
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space through the capillary bed as a function of perfusion and permeability. The contrast agent
that accumulates over time in the tumor can be then analyzed by MRI (Checkley et al., 2003;
Hahn et al., 2008). Recent animal studies suggest that parametric images providing information
on the morphology and function of the microvasculature of tumors can be obtained by GdDTPA–based DCE-MRI (Hillman et al., 2007).
DCE-MRI was performed using an orthotopic RCC model in athymic nude mice, which
was established by subcapsular renal implantation of Karmanos Cancer Institute-18 (KCI-18)
cells, a tumor cell line generated from a human papillary RCC specimen in our laboratory
(Hillman et al., 2007). Vascular changes induced by various doses of sunitinib in tumor-bearing
kidneys and normal contralateral kidneys were monitored by DCE-MRI and by histologic studies
of tissue sections.
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4.3 Materials and Methods
4.3.1 Orthotopic KCI-18/IK RCC Tumor Model
The human RCC cell line designated KCI-18 was established in our laboratory from a
primary renal tumor specimen obtained from a patient with papillary RCC (nuclear grade 3/4)
(Hillman et al., 2007). Cells were cultured in Dulbecco’s modified Eagle medium with
supplements (Hillman et al., 2007). After serial passages of KCI-18 cells in the kidney of nude
mice, highly tumorigenic KCI-18/IK were generated (Hillman et al., 2007). KCI-18/IK cells
were washed with Hank’s balanced salt solution and subcapsularly injected at a concentration of
5 × 105 cells in 30 μl of Hank’s balanced salt solution in the right kidney in 5- to 6-week-old
female BALB/C nu/nu nude mice (Harlan, Indianapolis, IN) (Hillman et al., 2007). Mice were
housed and handled under sterile conditions in facilities accredited by the American Association
for the Accreditation of Laboratory Animal Care. The animal protocol was approved by the
Animal Investigation Committee of Wayne State University.

4.3.2 Experimental Protocol
After injection of KCI-18/IK cells, a few mice were killed at early time points to assess
tumor growth before initiating treatment. Small tumors were detectable by days 9 to 10 in the
kidney. By days 10 to 12, mice bearing established kidney tumors (KTs) were treated with
sunitinib (Pfizer, Inc,New York,NY). The drug was prepared in a carboxymethyl cellulose
suspension vehicle, at dosages of 10, 20, or 40 mg/kg per day (SU10, SU20, or SU40,
respectively) and given orally by gavage, once a day. Control mice were treated with vehicle
only. Treatment was continued for 7 to 18 days. On the basis of initial experiments, early time
points of 7-day sunitinib treatment were selected for DCE-MRI studies or for monitoring RTKs
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expression to avoid incorrect analysis of advanced and large necrotic tumors in control mice. For
DCE-MRI experiments, three mice per treatment group were imaged. To assess the therapeutic
response of KTs to an optimal dosage of 40 mg/kg per day of sunitinib, 10 mice per experimental
group were treated daily for 18 days. For sunitinib dose-response studies, eight mice per
experimental group were treated daily with 10, 20 or 40 mg/kg per day of sunitinib. Mice were
killed by day 28 after tumor cell injection, when the tumor burden in control animals was large
(>1.5 cm × 1 cm in size compared with 0.7 cm × 0.25 cm for normal kidneys [NK]) to compare
with tumor sizes in treated groups. Tumor-bearing kidneys were resected and weighed (Hillman
et al., 2007).

4.3.3 Tissue Preparation for Histologic Diagnosis
At completion of experiments, mice were killed and KTs as well as the contralateral NKs
were resected and processed for histologic diagnosis. All tissues were fixed in 10% buffered
formalin, embedded in paraffin, and sectioned (Hillman et al., 2007). Sections were stained with
hematoxylineosin (H&E) (Hillman et al., 2007). Tissue sections were also immunostained with
anti-CD31 antibody (Ab; Thermo Scientific, Fremont, CA) using an avidin-biotin
immunoperoxidase technique (Haacke et al., 2007; Hillman et al., 2007; Raffoul et al., 2007).

4.3.4 DCE-MRI Monitoring of Tumor Perfusion and Permeability and Tumor Size in KTs
Mice from control and sunitinib-treated groups were imaged by DCE-MRI. Mice were
anesthetized by intraperitoneal injections of 0.35 ml of pentobarbital and 0.35 ml of ketamine at
a concentration of 52.5 mg/kg then a catheter was inserted into their tail vein, which was
attached to a syringe containing Gd-DTPA contrast agent (Magnevist, Berlex, Wayne, NJ). Mice
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were positioned on a cradle heated by temperature controlled water and were given a second low
dose of anesthetics of 15 mg/kg each in 0.1 ml to avoid motion problems while in the magnet. A
2-cm-diameter receive-only surface coil was placed over the tumor, and the cradle was placed
inside an 11-cm inner-diameter transmit-only volume coil. DCE-MRI of mice was performed in
the MR Research Facility at Wayne State University using a Bruker Biospec AVANCE animal
scanner (Bruker, Karlsruhe, Germany) equipped with a 4.7-T horizontal bore magnet and
actively shielded gradients. Anatomic imaging was done using a two-dimensional T2-weighted
spin-echo scan (repetition time = 2000 milliseconds, echo time = 52.4 milliseconds) to get an
overview of the kidney. Baseline imaging data of the kidneys were obtained using the shortrepetition time DCE scan for 30 time points (7 seconds between time points). On time point 10,
100 μl o f Gd-DTPA (0.125 mmol/kg) was injected into the tail vein catheter. This dose was
selected based on preliminary Gd dose-searching experiments to obtain appropriate contrast for
image analysis. Then, imaging data were acquired for 20 more time points. The imaging
parameters for this multislice two-dimensional gradient echo scan were as follows: repetition
time = 54.7 milliseconds, echo time = 2.9 milliseconds, flip angle = 30 degrees, field of view =
32 mm × 32 mm, slice thickness = 1.5 mm with 0.5-mm gap, matrix size = 128 × 128. Five
slices were collected for each animal. Data were processed to determine changes in contrast
agent uptake using the SPIN DCE software (Detroit, MI) (Haacke et al., 2007). For data analysis,
the full kidney was selected as the region of interest (ROI) for the KT and the contralateral left
NK. A threshold was selected to remove noise-only pixels in the image. Gd concentrations [C(t)]
in the tissue were calculated for all pixels in the ROI and for each time point. Data from the C(t)
curves were compiled for each pixel for 16 time points (112 seconds) after Gd injection to create
the initial area under the curve (IAUC). The distribution of IAUC for the entire ROI is then
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shown as a means to visualize the effects in every pixel in a single plot. The CIAUC is the
cumulative initial area under the curve of the IAUC histogram. For quantitative analysis of
vascular permeability, R50 (median) values are derived from CIAUC curves and correspond to
the concentration of Gd at which 50% of the pixels have been included (Haacke et al., 2007). To
evaluate the kinetics of uptake, washout, and leakage into the kidney tissue and tumor, the
parametric color maps are used to show the initial rate of uptake, peak concentration and
clearance of Gd in the tissue, and individual structures in each slice. The parameters measured in
DCE-MRI for sunitinib-treated tumors were compared with those obtained for control tumors
and NKs.

4.3.5 Statistical Analysis
Evaluation of the shape of the frequency distribution of tumor weights indicated that a
log transformation was required to meet the assumptions of normal theory tests. Two-sample ttests were used to assess the significance of differences in tumor weight between mice treated
with SU40 and control mice. A linear model with indicator variables to parameterize dose was
used to investigate the relationship of vehicle, SU dose, and tumor weight. The paired difference
in weight between the NK and KT was calculated and compared between experimental groups.
Adjustment for multiple comparisons between treatments was made using Holm’s procedure to
protect against inflated type I errors (Raffoul et al., 2007).
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4.4 Results
4.4.1 DCE-MRI of KTs
To investigate the effect of sunitinib on tumor vasculature, mice bearing KTs were
imaged by MRI before and after contrast Gd injection. We report the data of a representative
experiment comparing three dosages of sunitinib, namely, 10, 20, and 40 mg/kg per day, to
control mice treated with vehicle. These sunitinib dosages were selected based on previous
animal studies demonstrating that 40 mg/kg per day of sunitinib, given daily, is a biologically
active dosage.
For data analysis, the full kidney was selected as the ROI both for the right KT and the
left NK (Figure 4.1-A, T1). Gd concentrations [C(t)] were calculated for all pixels in each ROI
and for each time point, and the average C(t) over all pixels was plotted (Figure 4.1-B)(Haacke et
al., 2007). C(t) values, obtained after Gd injection, were integrated during 16 time points (112
seconds) to create the IAUC112 histograms (Figure 4.1-C) and CIAUC (Figure 4.1-D). In
control mice, Gd uptake was rapid in both the KT and NK. However, the kinetics of clearance of
Gd in the KT were slow compared with faster clearance in the NK (C(t) in Figure 4.1-B). Indeed,
the IAUC/CIAUC curves for the KT showed a pronounced shift to the right compared with NK,
indicative of a greater retention of Gd (Figure 4.1, C and D). DCE-MRI of mice treated with
SU40 revealed a pattern of Gd uptake that remained at a plateau with more retention of Gd in
both kidneys compared with control mice. Retention of Gd was still greater in the KT treated
with sunitinib than in the NK as observed by a shift to the right in IAUC/CIAUC curves relative
to NK, but this shift was less pronounced than in control tumors (Figure 4.1, C and D). In mice
treated with SU20, patterns of Gd uptake and clearance were identical in the KT and the NK
(Figure 4.1-B). SU20 mice had IAUC and CIAUC overlapping with those of the NK, indicative
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of improved tumor perfusion (Figure 4.1, C and D). Interestingly, the KT IAUC curve looked
more regular and shifted to the left compared with KTs in control or SU40-treated mice,
indicating decreased Gd retention. SU10 also seemed to change the kinetics of uptake and
clearance in KTs, showing a shift to the left in IAUC curves compared with control or SU40treated mice but less than with SU20-treated tumors (Figure 4.1, C and D). In the NK, SU10
caused milder changes in Gd uptake and clearance than SU20 or SU40 and resulted in an IAUC
pattern comparable to that of NK in control mice (Figure 4.1, C and D). It should be noted that
compared with tumors from control mice, sunitinib treatment at all tested dosages caused
significant shifts to the left of IAUC curves of KTs, which were more pronounced with lower
SU20 and SU10 doses than with a higher SU40 dose (as visualized relative to the black bar on
top of each graph in Figure 4.1-C).
Vascular changes in NKs were observed with higher SU20 and SU40 dosages and were
expressed by a shift to the right in IAUC curves compared with NKs of control mice. These data
presented for one mouse per treatment group were consistently observed for two additional mice
per group in the same experiment showing reproducibility of our findings.
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Figure 4.1. DCE-MRI of KCI-18 KTs. Mice bearing established tumors in the right kidneys were
treated every day for 7 days with vehicle only (control) or with sunitinib at dosages of 40, 20, or
10 mg/kg per day (SU40, SU20, or SU10, respectively). Then, mice were imaged by DCE-MRI
for 30 time points at 7-second intervals. (A) Baseline images were collected for the first during
10 time points before Gd contrast agent injection. At time point 10, Gd was injected in the tail
vein, and images were collected for 20 more time points. For data analysis, the full kidney was
selected as the ROI for the KT (blue contour on left of T1 image) and the contralateral left NK
(red contour on right of T1 image). A threshold was selected to remove noise only pixels in the
image. (B) The kinetics of Gd contrast uptake are represented in C(t) curves. (C) Data from the
C(t) curves were compiled for 16 time points (112 seconds) after Gd injection to draw IAUC112.
The small black bar indicates the peak position of NK in control mice and can be used as a
reference for curve shifting in NKs and KTs treated with sunitinib. (D) The CIAUC graphs were
derived from IAUC curves. In panels B, C, and D, blue lines are for KTs and pink lines are for
NKs. Data from a representative mouse from each treatment group are presented.
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To compare the patterns of Gd uptake in KTs versus NKs, R50 values for three mice per
treatment group were derived from CIAUC curves for both KTs and NKs (Figure 4.2). The R50
(median) values correspond to the concentration of Gd at which 50% of the pixels have been
included (Figure 4.2-A) (Haacke et al., 2007). A trend in lower R50 values was observed in
SU10- and SU20-treated mice compared with control mice and SU40-treated mice for both R50
of KTs (Figure 4.2-B) and NKs (Figure 4.2-C). R50 values of KTs were then normalized to the
R50 values of contralateral NKs for each mouse and shown as normalized R50 values (NR50)
for three mice per group (Figure 4.2-D) (Haacke et al., 2007).We found that NR50 of KTs
relative to NKs were consistently much smaller in SU20-treated mice in a range of 0.04 to 0.08
compared with a wide range of 0.12 to 0.43 in SU10-treated, SU40-treated, or control mice
(Figure 4.2-D). When NR50 was calculated as R50 values of KTs from sunitinib-treated mice
relative to KTs from control mice, NR50 of SU20-treated mice was consistently lower than that
of SU40-treated mice (Figure 4.2-E). A trend to lower NR50 values was also observed with
SU10-treatedmice (Figure 4.2-E). To assess the effect of sunitinib on contralateral NKs, R50
values of NKs from mice treated with sunitinib were normalized to NKs from control mice
(Figure 4.2-F). TheseNR50 data of NKs showed lower values for SU10- and SU20-treated mice
compared with SU40-treated mice (Figure 4.2-F).
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Figure 4.2. R50 quantitation of DCE-MRI data of KCI-18 KTs. (A) The R50 value is derived
from CIAUC curves (as shown for control mouse) and corresponds to the Gd concentration at
which 50% of the pixels have been included. (B) R50 of KTs from three mice per treatment
group. (C) R50 of contralateral NK from the same three mice per treatment group shown in panel
B. (D) NR50 of KT versus NK: NR50 represents normalization of R50 values of KTs relative to
R50 values of contralateral NK calculated as [R50KT− R50NK] / R50NK for each mouse and
shown for three mice per group. (E) NR50 of KTSU versus KTCONT: Normalization of R50
values of KTs from mice treated with sunitinib (KTSU) relative to the mean R50 values of KTs
from control mice (KTCONT) calculated as [R50 KTSU− R50 KTmean cont] / R50 KTmean
cont for each mouse and shown for three mice per treatment group. (F) NR50 of NKSU versus
NKCONT: Normalization of R50 values of NKs of mice treated with sunitinib relative to the
mean R50 values of NKs from control mice calculated as [R50 NKSU
− R50 NKmean cont] /
R50 NKmean cont for each mouse and shown for three mice per treatment group. Data are
presented for three mice per treatment group from the same experiment shown in Figure 4.1.
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4.4.2 DCE-MRI Analysis of Gd Kinetics of Uptake and Clearance Using Parametric Color
Maps
The parametric color maps from control mice showed accumulation of Gd in the
periphery of the tumor with no uptake in the core of the tumor (Figure 4.3). In the NK of control
mice, Gd uptake was distributed in the entire kidney with a higher uptake in the medullary
central area than in the peripheral cortex, probably reflecting normal secretion of contrast agent
(Figure 4.3). The negative slope image (Nslope) represents the clearance kinetics of Gd and
shows low levels in control mice. The kidneys of SU40-treated mice showed a strong
accumulation of Gd in most of the KT with persisting high levels in the peak, slope, and washout
slope images (Figure 4.3). This effect was also observed in the NK with increased levels of Gd in
both cortex and medulla, indicating that this high dosage of sunitinib also alters the perfusion of
NK tissue. Parametric color maps of SU20-treatedmice showed a significant accumulation of Gd
in the KT including Gd uptake in the tumor (Figure 4.3). These levels were high in the peak,
slope, and Nslope images. Similar findings were observed in NK treated with SU20 (Figure 4.3).
In contrast, KTs from SU10-treated mice showed no uptake of Gd in the core of the tumor, but
some was seen at its periphery similar to KTs from control mice (Figure 4.3). Low levels were
observed in the peak, slope, and Nslope images. The NK of mice treated with SU10 showed
more Gd in the medulla than in the cortex (Figure 4.3) as seen in NK of control mice. These
findings were consistently observed in two additional mice per group.
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Figure 4.3. DCE-MRI of KTs: Parametric color maps. Parametric color maps were constructed
based on uptake and concentration of Gd in the tissue, represented by the colors blue, green,
yellow, and red with gradual increase of Gd from lowest values (blue) to highest values (red).
Data are presented for the same representative mouse from each treatment group shown in Figure
4.1. The KT is on the left, and the contralateral NK is on the right of the MR images. The color
coding in the kidneys are shown for IAUC, the peak, and the slope of C(t). The Nslope
represents the clearance of Gd after reaching the peak in the tissue.
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4.4.3 Therapeutic Response of KTs to Sunitinib
Previous studies using sunitinib in mouse tumor models have demonstrated that dosages
of 40 or 80 mg/kg per day were optimal and biologically active, leading to tumor inhibition and
inhibition of phosphorylation of RTKs on cancer cells and endothelial cells (Abrams et al.,
2003). Therefore, for our initial studies, we selected to test an optimal dosage of 40 mg/kg per
day of sunitinib to investigate the therapeutic response of KTs using our KCI-18 RCC model.
After intrarenal injection of KCI-18 cells, by days 10 to 12, mice developed established KTs
with a mean (SD) volume of 150 (7) mm3 and mean (SD) weight of 186 (4) mg compared with
NK volume of 125 (2) mm3 and weight of 148 (12) mg. At that time point, mice were treated
daily with 40 mg/kg per day of sunitinib. On day 28 after cell injection, the right KT and the left
NK were weighed (Figure 4.4-A). On average, KTs in control animals were 822 mg heavier than
the contralateral NK. After sunitinib treatment, KTs were significantly smaller compared with
control mice (P =0001; Figure 4.4-A). On average, SU40-treated tumors were 75%smaller than
tumors in control mice but were still significantly larger compared with the contralateral NKs,
with a mean (SD) difference of 209 (105) mg (P < .0001; Figure 4.4-A, inset). The weight
disparity between the tumor-bearing and the NK was significantly smaller in mice treated with
SU40 compared with control animals (P = .0002). By gross observation, control mice showed
very large and extremely vascularized tumors that invaded the entire kidney and grew into the
abdominal cavity (Figure 4.4-A, inset). After sunitinib treatment, the shape of the kidney was
preserved in KTs indicating that SU40 therapy controlled the growth and invasion of the tumor
through kidney tissue, but the kidneys looked ischemic. DCE-MRI findings suggest that lower
doses of sunitinib have a different effect on tumor perfusion; therefore, in additional separate
experiments, a dose-response study of sunitinib was tested, and a representative experiment is
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presented in Figure 4.4-B. The therapeutic efficacy of lower dosages of 10 or 20 mg/kg per day
of sunitinib was evaluated and compared with that of 40 mg/kg per day. SU10 did not
significantly control KT growth (P = .43); tumors were only 25% smaller than control tumors on
average (Figure 4.4-B) and appeared more hemorrhagic by gross observation. Both SU20 and
SU40 significantly inhibited KT growth; average growth inhibition was 57% and 66%,
respectively, relative to control tumors (P = .003 and P = .0007, respectively; Figure 4.4-B). On
average, tumors of SU20-treated mice were 43% smaller than tumors of SU10-treated mice, but
the difference is only marginally significant (P = .05). Although the tumors of SU40- treated
mice were not significantly smaller than those of SU20-treated mice (P = .55), the variation in
tumor size from mouse to mouse was smaller in SU40-treated mice (Figure 4.4-B). The extent of
tumor growth inhibition mediated by SU40 was comparable in these two series of independent
experiments presented in Figure 4.4, A and B, confirming reproducibility of our findings.
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Figure 4.4. KCI-18 KT response to sunitinib. Mice bearing established KTs were treated daily
with sunitinib for 18 days, then tumors were resected and weighted. (A) Response to optimal
dose of sunitinib. The kidney weights and their median are reported for 10 mice per group
treated with vehicle (control) or sunitinib at 40 mg/kg per day (SU40) compared with the
contralateral NK weights in each experimental group. Inset contains pictures of KTs of control
mice or SU40-treated mice compared with NKs. (B) Sunitinib dose-response. The kidney
weights and their median are reported for eight mice per group treated with vehicle (control) or
sunitinib at dosages of 40, 20, or 10mg/kg per day (SU40, SU20, or SU10, respectively)
compared with the contralateral NK weights in each experimental group. *P < .05. Data
presented were obtained from separate representative experiments.
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4.4.4 Effect of Sunitinib on the Vasculature of KTs
For histologic studies, KT sections were stained with H&E or by immunostaining with
anti-CD31 Ab for the detection of blood vessels. KTs presented as high-grade carcinomas,
consisting of tumor cells with large pleomorphic nuclei, prominent nucleoli, abundant
eosinophilic cytoplasm, and large cytoplasmic inclusions (Figure 4.5-A, Control) (Hillman et al.,
2007). These tumors were highly vascularized with a sinusoidal vascular pattern and abnormal
enlarged vessels as seen both by H&E staining and anti- CD31 staining (Figure 4.5, A and B,
Control). Tumors treated with SU40 showed areas of tumor destruction and necrosis associated
with hemorrhages but also remaining areas of viable tumor cells (Figure 4.5-A). The destruction
of tumor vasculature was confirmed by anti-CD31 staining with disruption of the vessel walls,
release of red blood cells in the tumor, and minimal staining of endothelial cells by anti-CD31
(Figure 4.5-B). KTs treated with SU20 clearly showed more regularized and thinner vessels by
H&E, and staining of endothelial cells in the vessel walls by anti-CD31 (Figure 4.5, A and B) in
contrast to the enlarged abnormal vessels observed in KTs from control mice. However, tumors
treated with SU10 still contained enlarged abnormal vessels as confirmed by anti-CD31 staining
(Figure 4.5, A and B), and some of them were comparable to those observed in control mice.
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Figure 4.5. Histologic diagnosis of KCI-18 KTs treated with various dosages of sunitinib. KTs
resected from mice for the experiments described in Figure 4.4 were processed for histologic
diagnosis, and tumor sections were stained either with H&E (A) or with anti-CD31
immunostaining (B). H indicates hemorrhages; N, necrosis; T, tumor; V, vessels. Control
untreated tumors consisted of tumor cells with large pleomorphic nuclei and were highly
vascularized with a sinusoidal vascular pattern and abnormal enlarged vessels. Tumors treated
with SU40 showed areas of tumor destruction and necrosis associated with hemorrhages and
areas of viable tumor cells. Tumor sections stained with anti-CD31 reveal destruction of tumor
vasculature and disruption of the vessel walls. KTs treated with SU20 showed more regularized
and thinner vessels both by H&E and by anti-CD31 staining. SU10-treated tumors show enlarged
abnormal vessels as confirmed by anti-CD31 staining with staining of areas of endothelial cells
lining vessel walls. Original magnifications, ×40.
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4.4.5 Effect of Sunitinib on Vasculature of NK Tissue
Histologic analysis of NKs obtained from control mice showed multiple regular and thin
vessels by H&E (Figure 4.6-A) and clear structures of vessels delineated by anti-CD31 staining
of endothelial cells in vessel walls (Figure 4.6-B). In contrast, NKs obtained from mice treated
with the high SU40 dosage showed dilatation of blood vessels as seen by H&E (Figure 4.6-A).
Some enlarged vessels showed disruption of vessel walls as observed by anti-CD31 staining
(Figure 4.6-B). The effect of SU20 on normal vessels in NKs was mild and caused dilatation
only in a few vessels, whereas most looked normal as seen by anti-CD31 staining, in contrast to
the numerous vessels enlarged by SU40 treatment (Figure 4.6, A and B). No effect on vessels in
the NK was observed with SU10; the vessels looked thin and regular and were comparable to
those seen in NKs of control mice (Figure 4.6, A and B). It should be noted that although
disruptions in normal vessels were observed after sunitinib therapy, the mice treated with
dosages of 20 to 40 mg/kg per day showed no apparent signs of drug toxicity.
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Figure 4.6. Histologic diagnosis of NKs from mice treated with various doses of sunitinib. The
contralateral left NKs (not bearing a tumor) resected from mice of the experiments described in
Figure 4.4 were processed for histologic diagnosis, and kidney tissue sections were stained either
with H&E (A) or with anti-CD31 immunostaining (B).NKs obtained from control mice showed
multiple regular and thin vessels (V) by H&E and clear structures of vessels delineated by antiCD31 staining of endothelial cells in vessel walls. After high SU40 dosage, dilatation of blood
vessels was observed as seen by H&E. Enlarged vessels sometimes showed disruption of vessel
walls seen by anti-CD31 staining. The milder effect of SU20 on normal vessels in NKs caused
dilatation only in a few vessels, whereas most looked normal as seen by anti-CD31 staining. No
effect on vessels in the NK was observed with SU10; the vessels looked thin and regular.
Original magnifications, ×40.
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4.5 Discussion
To design novel targeted therapies for metastatic RCC, extensive research is ongoing to
test drugs that target both the tumor cells and the tumor vasculature to inhibit processes that
stimulate tumor growth in the tumor microenvironment. Antiangiogenic therapy causing
excessive vascular regression could compromise the delivery of drugs or oxygen in the tumor
when combined with conventional cytotoxic therapies (Jain, 2001; Jain, 2005). Using a
preclinical RCC model, we have investigated, by DCE-MRI, vascular changes in KTs induced
by the antiangiogenic drug sunitinib to select doses that could induce transient vessel
normalization by pruning inefficient blood vessels and thereby improve tumor blood flow and
subsequent drug delivery to tumor cells by chemotherapy (Browder et al., 2000; Wildiers et al.,
2003; Tong et al., 2004).
A dose-dependent therapeutic efficacy of sunitinib for KCI-18 RCC tumor xenografts
was demonstrated with dosages of 20 and 40 mg/kg per day, causing a significant
inhibition/arrest of tumor growth and limited invasion of the kidney by tumor cells, in agreement
with previous preclinical animal studies (Abrams et al., 2003; Murray et al., 2003; O'Farrell et
al., 2003; Xu et al., 2005). Sunitinib exerted a direct cytotoxic effect at doses greater than 0.5 μM
in KCI-18 cells in vitro. As documented in clear cell RCC and papillary RCC human tumor
specimens (Lam et al., 2005; Xu et al., 2005), we found that KCI-18 cells and tumors also
expressed the VEGFR-2 and PDGFR-β RTKs targets of sunitinib. Increasing doses of sunitinib
caused a lower expression of these receptors on KTs, probably due to the modulation of these
receptors. These findings suggest that sunitinib could inhibit KCI-18 tumor growth through
targeting of RTKs signaling on tumor cells and/or on endothelial cells or stromal cells resulting
in direct antitumor and antiangiogenic activities as shown in other studies. Interestingly,
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modulation of RTKs receptors by sunitinib was also observed on NK tissues, confirming the
effect of the drug on the vasculature of normal tissues. In agreement with our findings, recent
animal studies (Ebos et al., 2007) and clinical trials of sunitinib for metastatic RCC or breast
cancer reported decreased soluble VEGFRs’ plasma levels (Burstein et al., 2008; Rini et al.,
2008), which suggested modulation of VEGF pathway biomarkers by sunitinib. Furthermore,
previous pharmacokinetic studies in mouse xenograft models demonstrated plasma levels of 50
to 100 ng/ml for 12 hours when mice were treated with the same efficacious dosages of 20 to 40
mg/kg per day of sunitinib as used in our studies, resulting in the inhibition of VEGFR-2 and
PDGFR-β RTKs. Comparable plasma levels of 50 to 100 ng/ml of sunitinib were also measured
in pharmacokinetic studies of patients receiving 50-mg daily doses (Britten et al., 2008).
Sunitinib also induced dose-dependent vascular changes, which were observed both in
KTs and in NK tissues by DCE-MRI. In control mice, the clearance of Gd in the KT was slow
compared with faster clearance in the NK, probably as a result of leakiness from the abnormal
enlarged tumor vessels observed histologically. Parametric maps from control mice showed
accumulation of Gd in the periphery of the tumor with no uptake in the core of the tumor,
indicative of poor vascularity and perfusion in the core of the tumor as shown in other MRI
studies of xenograft tumors (Checkley et al., 2003; Marzola et al., 2005). In contrast, the NK of
control mice showed distribution of Gd in the entire kidney with lower uptake in the peripheral
cortex and a higher uptake in the medulla probably due to greater numbers of vessels in that area
and reflecting normal secretion of contrast agent. Compared with control tumors, KTs from mice
treated with a low dosage of 10 mg/kg per day of sunitinib showed mild changes in Gd uptake
and clearance kinetics of KTs. These SU10- treated tumors had also poor tumor perfusion in the
core of the tumor and histologically showed enlarged abnormal vessels similar to findings
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observed in control tumors. Likewise, SU10 caused minimal effect on NK tissue vasculature
with no changes in vascular permeability or vessel morphology compared with control mice.
A therapeutic high dosage of 40 mg/kg per day induced vascular permeability changes
resulting in retention of Gd in both left and right kidneys. Gd retention was greater in the KT
than in the NK. This increased vascular permeability of Gd in the tumor could be due to the
damaged vasculature and leakage of Gd into surrounding kidney tissue with slow kinetics of
washout. Histologic studies confirmed destruction of tumor vasculature of SU40-treated KTs and
disruption of the vessel walls causing hemorrhages. It should be noted that increased levels of Gd
were also observed in both cortex and medulla of NKs, indicating that this high SU40 dosage
alters the kinetics of uptake and contrast clearance of NK tissue. These data are supported by
histologic observation of dilatation and disruption of normal vessels detected by anti-CD31 Ab
staining of NK tissue. We conclude that the dosage of 40 mg/kg per day of sunitinib causes
excessive vascular damage and vascular permeability in KTs and alterations of NK vessels. This
in turn suggests that this dosage is not appropriate for combination chemotherapies.
After treatment with an intermediate sunitinib dosage of 20 mg/kg per day, improved Gd
clearance was observed with less Gd retention than that seen with SU40 or in control mice.
Interestingly, in SU20- treated mice, Gd uptake and clearance in the C(t) curves, IAUC, and
CIAUC showed identical patterns in the KT compared with the NK as confirmed by the low R50
value of KTs relative to the R50 value of NKs (Figure 4.2-D). A clear shift to the left of IAUC
curves of SU20- treated mice was observed compared with control mice and SU40- treated mice
as shown also by the low R50 value of KTs treated with SU20 relative to the R50 value of
control KTs (Figure 4.2-E). These data suggest a return to more “normal vasculature” with lower
permeability (i.e., less leaky vessels) after treatment with SU20. Interestingly, a similar pattern
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was observed in NKs of mice treated with sunitinib compared with those of control mice
showingNR50 values lower for SU20-treated mice than for SU40-treated mice, indicating a
milder effect of SU20 dosage on vasculature of NK tissue (Figure 4.2-F). Parametric maps
revealed increased Gd uptake in the core of the tumor and surrounding kidney tissue in SU20treated mice. Histologically, the vessels of KTs treated with SU20 clearly showed more
regularized and thinner vessels, indicating pruning or normalization of tumor vessels compared
with the enlarged vessels of control KTs. The effect of SU20 on vessels in NKs was mild and
caused dilatation only in a few vessels.
To assess our results statistically, one way ANOVA was performed on the data from
Figure 4.2-D to examine the differences in the normalized ratio of the mean value of the CIAUC
curve (NR50) between the kidney tumor (KT) and normal kidney (NK) for all mice treated with
a dose of 40, 20 or 10 mg/kg/day sunitinib or treated with vehicle only. The subject inclusion
criterion for analysis is defined by the changes of R50 values for the kidney tumors relative to
R50 values in the normal kidney. There were a total of 12 mice used in the final analysis, 3 per
each group. With this sample size, there is only a marginally significant difference between the
KT group treated with sunitinib at a dose of 20 mg/kg/day and the control group (F (12, 3) =
1.83, p = 0.058). There was no significant difference between controls and other mice treated
with a sunitinib dose at either 10 or 40 mg/kg/day. Clearly an increased sample size might show
more significant results. This would be necessary if we have to verify the claim that RCC
treatment with an intermediate dose of 20 mg/kg/day sunitinb offers enhancement in kidney
tumor perfusion with less impact in the normal kidney over a conventional treatment dose of 40
mg/kg/day sunitinb
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In summary, imaging of tumor vasculature changes by DCE-MRI and histologic
diagnosis indicates that a lower dosage of 20 mg/kg per day of sunitinib could cause “pruning”
or normalization of the tumor vasculature allowing for better tumor perfusion and decreased
leakiness of vessels. Moreover, this dosage caused only mild vascular changes in normal tissues
and thus could be less toxic to normal vessels, suggesting that this dosage could be used for
combination with chemotherapy or radiotherapy.
Our histologically verified studies demonstrate that the use of DCE-MRI is a useful
means for monitoring vascular changes induced by sunitinib in both tumors and normal tissues.
These data can be used to select the dose and schedule of sunitinib and potentially other
antiangiogenic drugs causing transient normalization of tumor vasculature for combination
therapies.

63
Chapter Five
DCE-MRI Imaging of Sunitinib-Induced Vascular Changes to Schedule Chemotherapy in
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5.1 Abstract
In an attempt to develop better therapeutic approaches for metastatic renal cell carcinoma
(RCC), the combination of the anti-angiogenic drug sunitinib with gemcitabine was studied.
Using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), we have previously
determined that a sunitinib dose of 20mg/kg/day increased kidney tumor perfusion and decreased
vascular permeability in a pre-clinical murine RCC model. This sunitinib dose causing
regularization of tumor vessels was selected to improve delivery of gemcitabine to the tumor.
DCE-MRI was used to monitor regularization of vasculature with sunitinib in kidney tumors to
schedule gemcitabine. We established an effective and non-toxic schedule of sunitinib combined
with gemcitabine consisting of pre-treatment with sunitinib for 3 days followed by four
treatments of gemcitabine at 20mg/kg given 3 days apart while continuing daily sunitinib
treatment. This treatment caused significant tumor growth inhibition resulting in small residual
tumor nodules exhibiting giant tumor cells with degenerative changes, which were observed both
in kidney tumors and spontaneous lung metastases, suggesting a systemic anti-tumor response.
The combined therapy caused a significant increase in mouse survival. DCE-MRI monitoring of
vascular changes induced by sunitinib, gemcitabine and both combined showed increased tumor
perfusion and decreased vascular permeability in kidney tumors. These findings, confirmed
histologically by thinning of tumor blood vessels, suggest that both sunitinib and gemcitabine
exert anti-angiogenic effects in addition to cytotoxic anti-tumor activity. These studies show that
DCE-MRI can be used to select the dose and schedule of anti-angiogenic drugs to schedule
chemotherapy and improve its efficacy.
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5.2 Introduction
Recent developments in anti-angiogenic therapy have improved targeting metastatic renal
cell carcinoma (RCC). The incidence of RCC has increased in recent years with approximately
54,390 new cases each year in the United States of America. The disease is responsible for an
estimated 13,010 deaths each year (Jemal et al., 2008). Nearly half of the patients present with
localized disease that can be treated by surgical removal (Haas and Hillman, 1996; Motzer et al.,
1996). However, one third of the patients have metastatic disease at first presentation, and 2030% of the patients treated for localized RCC subsequently develop metastatic disease which
frequently involves the lungs (Haas and Hillman, 1996; Motzer et al., 1996).
The drug sunitinib (SU11248 or Sutent) is a small molecule receptor tyrosine kinase
(RTK) inhibitor that has been approved by the FDA in January 2006 for RCC treatment based on
significant responses in multiple metastatic sites and in primary tumors in initial clinical trials for
metastatic RCC (Motzer et al., 2006). We and others have demonstrated that sunitinib targets and
inhibits signaling of several RTKs including PDGFR, VEGFR, KIT and FLT3 in mouse
xenograft models (Hillman et al., 2009). Sunitinib exhibits direct anti-tumor activity by
inhibiting RTKs that are expressed by cancer cells and are involved in signaling for cancer cell
proliferation (Abrams et al., 2003; Mendel et al., 2003; Murray et al., 2003; O'Farrell et al.,
2003; Sohal et al., 2003; Hillman et al., 2009). Sunitinib also exhibits anti-angiogenic activity by
inhibition of signaling through VEGFR-2 and PDGFR-β RTKs expressed on endothelial cells or
stromal cells (Mendel et al., 2003; Huang et al., 2010).
In a phase III multinational study of 750 patients with metastatic RCC, randomized to
sunitinib or interferon alfa (IFNα), the response rate to sunitinib was 31%, with median
progression free survival (PFS) of 11.7 months and a median survival of 28 months (Motzer et
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al., 2007). A recent update of this trial documented an objective response rate (ORR) of 47%
with 11 months median PFS for sunitinib vs 12% ORR and 5 months PFS for IFNα (Motzer et
al., 2009). Although the results with sunitinib therapy are impressive, long-term control of the
disease is still not achieved. Additionally, several trials documented adverse effects of
cardiotoxicity in some of the patients, probably as a result of alterations to normal vasculature
(Chu et al., 2007; Kollmannsberger et al., 2007; Schmidinger et al., 2008; Telli et al., 2008).
Therefore, further investigations with sunitinib dose adjustments and combination with other
cytotoxic drugs are warranted to decrease the impact on vital organs such as the heart and the
kidney.
The process of tumor angiogenesis involves proliferation of abnormal vessels that are
enlarged, disorganized and leaky due to defective basement membrane. These structural defects
of tumor vessels cause increased interstitial tissue pressure, impaired blood supply and decreased
oxygen supply in tumors compromising the delivery and efficacy of cytotoxic drugs and
radiotherapy (Jain, 2001; Jain, 2005). To increase the efficacy of chemotherapy, we have
recently investigated various doses of sunitinib to cause only partial destruction of immature and
inefficient blood vessels leading to “normalization” of tumor vasculature and improve the blood
flow in tumors (Hillman et al., 2009). We used dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) to image vascular changes induced by sunitinib within the tumor, in an
orthotopic KCI-18 model of human RCC xenografts in nude mice. DCE-MRI is a non-invasive
approach, currently used in humans, that can detect early changes in the tumor induced by antiangiogenic therapy as reported in human studies (Yankeelov et al., 2007; Hahn et al., 2008) and
in preclinical animal models (Checkley et al., 2003; Marzola et al., 2005). This method measures
a combination of tumor perfusion and vessel permeability and allows the detection of changes in
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tumor vascularity, which occur at a much earlier stage in the treatment of tumors with antiangiogenic drugs than does shrinkage of tumor mass.
By assessing vascular changes by DCE-MRI, we showed that a suboptimal daily
sunitinib dose of 20mg/kg/day mildly affected normal vessels but caused better tumor perfusion
and decreased vascular permeability, in agreement with histological observations of thinning and
regularization of tumor vessels (Hillman et al., 2009). The goals of the current study were to
determine if using sunitinib at doses which regularize the blood flow in the tumor in conjunction
with the cytotoxic drug gemcitabine could improve its therapeutic efficacy for RCC.
Gemcitabine is a pyrimidine analogue that inhibits DNA synthesis. The antitumor activity of
gemcitabine depends on a series of sequential phosphorylations leading to accumulation of
gemcitabine diphosphate and triphosphate which interfere with DNA elongation by competing
with dCTP and also inhibit ribonucleotide reductase, thus reducing the pool of
deoxyribonucleotide triphosphates. A few clinical trials have used gemcitabine in combination
with other chemotherapy drugs including fluorouracil, thalidomide and capecitabine or with the
cytokine interferon alpha for metastatic renal cell carcinoma (Desai et al., 2002; Perez-Zincer et
al., 2002; Amato and Khan, 2008; Tannir et al., 2008). These trials resulted in modest clinical
benefit.
Although gemcitabine is a potent anti-tumor drug, its activity may be reduced by poor
access to tumor cells caused by tumor vessel leakiness and increased interstitial tissue pressure
(Jain, 2001; Jain, 2005). In the current study, we have investigated whether improving blood
flow by sunitinib, at doses which regularize tumor vessels, could enhance the efficacy of
gemcitabine for RCC in murine xenografts kidney tumors. DCE-MRI was used to monitor
vascular changes induced by pre-treatment with sunitinib in KCI-18 kidney tumors to schedule
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initiation of chemotherapy. We determined the dose and schedule of the combination of antiangiogenic therapy with sunitinib and cytotoxic therapy with gemcitabine that result in
significant long lasting anti-tumor response. Vascular changes caused by gemcitabine treatment
as a single modality or combined with sunitinib were evaluated by DCE-MRI.
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5.3 Materials and Methods
5.3.1 Orthotopic KCI-18/IK RCC Tumor Model
The human RCC cell line designated KCI-18 was established in our laboratory from a
primary renal tumor specimen obtained from a patient with papillary RCC (nuclear grade III/IV)
(Hillman et al., 2004). Cells were cultured in DMEM medium with supplements (Hillman et al.,
2004). Following serial passages of KCI-18 cells in the kidney of nude mice, highly tumorigenic
KCI-18/IK RCC cell lines were generated (Hillman et al., 2004). KCI-18/IK cells were washed
with HBSS and subcapsularly injected at a concentration of 5x105 cells in 30 µl HBSS in the
right kidney in 5-6 week old female BALB/C nu/nu nude mice (Harlan, Indianapolis, IN)
(Hillman et al., 2004). Mice were housed and handled under sterile conditions in facilities
accredited by the American Association for the Accreditation of Laboratory Animal Care. The
animal protocol was approved by Wayne State University Animal Investigation Committee.

5.3.2 Experimental Protocol
After injection of KCI-18/IK cells, a few mice were sacrificed at early time points to
assess tumor growth before initiating treatment. Small tumors were detectable by day 9-10 in the
kidney. On day 10, mice bearing established kidney tumors were treated with sunitinib (Pfizer
Inc, New York, NY). The drug was prepared in a carboxymethyl cellulose suspension vehicle, at
a dose of 20 mg/kg/day (SU20) and given orally by gavage, once a day (Hillman et al., 2009).
Control mice were treated with vehicle only. After sunitinib pre-treatment for 3 days, mice were
treated with various doses of gemcitabine administered 2-3 times a week by intraperitoneal (i.p.)
injections. Gemcitabine (Gemzar, from Eli Lilly, Indianapolis, IN) was reconstituted in PBS and
prepared at doses of 10-50mg/kg. Sunitinib treatment was continued daily for the duration of the
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experiment. To assess the therapeutic response of kidney tumors to a combination of sunitinib
and gemcitabine, 6-8 mice per experimental group were treated. Mice were killed by day 28 after
tumor cell injection, when the tumor burden in control animals was large (greater than 1.5cm x
1cm in size compared to 0.7cm x 0.25cm for normal kidney) to compare with tumor sizes in
treated groups (Hillman et al., 2009). The tumor-bearing right kidneys and the contralateral left
normal kidneys were resected and weighed (Hillman et al., 2009). For survival studies, 12 mice
per experimental group were treated with sunitinib at 20mg/kg/day for 3 days on day 10-12 after
KCI-18 cell injection in the kidney. Then, mice received five gemcitabine treatments at 20 mg/kg
given 3-4 days apart, on days 13, 16, 20, 23 and 27. Sunitinib was continued daily for five days a
week, for 6 weeks, up to 50 days. Mice were monitored daily for survival and sick animals were
killed and autopsied (Haacke et al., 2007). On day 50, all remaining mice were killed and tumorbearing kidneys were resected and weighted.

5.3.3 Tissue Preparation for Histology
At completion of experiments, mice were killed and tumor-bearing kidneys, normal
contralateral kidneys and the lungs were resected and processed for histology. All tissues were
fixed in 10% buffered formalin, embedded in paraffin and sectioned (Hillman et al., 2009).
Sections were stained with hematoxylin-eosin (H&E) (Hillman et al., 2009).

5.3.4 DCE-MRI Monitoring of Tumor Perfusion and Permeability and Tumor Size in
Kidney Tumors
Based on initial experiments, early time points between 3 and 11 days after initiation of
sunitinib treatment (day 14 through day 21 post tumor cell implantation) were selected for DCE-
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MRI studies to avoid incorrect analysis of advanced and large necrotic tumors in control mice.
Three mice from control, sunitinib and gemcitabine treated groups were imaged by DCE-MRI.
Mice were anesthetized by i.p. injections of 0.35 ml pentobarbital and 0.35ml ketamine at a
concentration of 52.5mg/kg then a catheter was inserted into their tail vein, which was attached
to a syringe containing Gd-DTPA contrast agent (Berlex, Wayne, NJ). Mice were positioned on
a cradle heated by temperature-controlled water and were given a second low dose of 15mg/kg
anesthetics (in 0.1ml volume) to avoid motion problems while in the magnet (Hillman et al.,
2009). A 2-cm diameter receive-only surface coil was placed over the tumor and the cradle was
placed inside an 11-cm inner diameter transmit-only volume coil. DCE-MRI of mice was
performed in the MR Research Facility at Wayne State University, using a Bruker Biospec
AVANCE animal scanner equipped with a 4.7 –T horizontal bore magnet and actively shielded
gradients. Anatomical imaging was done using a 2D T2 weighted spin echo scan (TR = 2000ms,
TE = 52.4ms) to get an overview of the kidney (Hillman et al., 2009). Baseline imaging data of
the kidneys were obtained using the short TR DCE scan for 30 time points (7 sec between time
points). On time point 10, 100 µl of Gd-DTPA (0.125 mmole/kg) was injected into the tail vein
catheter. This dose was selected based on preliminary Gd dose searching experiments to obtain
appropriate contrast for image analysis (Hillman et al., 2009). Then, imaging data were acquired
for 20 more time points. The imaging parameters for this multi-slice 2D gradient echo scan were:
TR = 54.7ms, TE = 2.9ms, FA = 30o, FOV= 32mm x 32mm, slice thickness = 1.5mm with
0.5mm gap, matrix size = 128x128. Five slices were collected for each animal. Data were
processed to determine changes in contrast agent uptake using the SPIN DCE software (Detroit,
MI) (Haacke et al., 2007). For data analysis, the full kidney was selected as the region of interest
(ROI) for the tumor-bearing kidney and the contralateral left normal kidney. A threshold was
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selected to remove noise only pixels in the image (Hillman et al., 2009). Gd concentrations [C(t)]
in the tissue were calculated for all pixels in the ROI and for each time point (Raffoul et al.,
2007). Data from the C(t) curves were compiled for each pixel for 16 time points (112sec) after
Gd injection to create the initial area under the curve (IAUC). The distribution of IAUC for the
entire ROI is then shown as a means to visualize the effects in every pixel in a single plot. The
CIAUC is the cumulative initial area under the curve of the IAUC histogram (Hillman et al.,
2009). For quantitative analysis of vascular permeability, R50 (median) values are derived from
CIAUC curves and correspond to the concentration of Gd at which 50% of the pixels have been
included (Raffoul et al., 2007). To evaluate the uptake, wash-out and leakage of Gd into the
tumor and surrounding kidney tissue, the parametric color maps are used to show the total Gd
uptake (AUC) in individual structures. The parameters measured in DCE-MRI for sunitinib and
or gemcitabine treated tumors were compared to those obtained for control tumors and normal
kidneys.

5.3.5 Statistical Analysis
Evaluation of the shape of the frequency distribution of tumor weights indicated that a
log transformation was required to meet the assumptions of normal theory tests. Linear models
were used to assess the statistical significance of differences in tumor weight between
experimental groups and proportional hazards models were used for survival data. In both
models, indicator variables were used parameterize dose. Adjustment for multiple comparisons
between treatments was made using Holm’s procedure to protect against inflated type I errors.
Kaplan-Meier methods were used to graphically compare survival in each of the groups. The
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log-rank test was used to test differences in survival distributions between groups again using
Holm’s procedure to control for type I error rate.
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5.4 Results
5.4.1 Direct Cytotoxic Effect of Sunitinib Combined With Gemcitabine in KCI-18 Cells in
Vitro
We have previously shown that sunitinib exerts a direct cytotoxic effect on KCI-18 RCC
in vitro, in a dose-dependent manner (Hillman et al., 2009). We found that a dose of 1 µM
sunitinib caused a significant 40% inhibition in cell survival in a clonogenic assay, as confirmed
in this additional experiment (Table 5.1). This dose was selected to investigate whether this
effect is enhanced by the addition of gemcitabine. Following pilot titration experiments,
suboptimal doses of gemcitabine were tested alone and combined with sunitinib in a clonogenic
assay. Gemcitabine at doses of 1 and 2.5 µM caused significant inhibition of KCI-18 cell
survival of about 50% (p<0.001) and 70% (p<0.0001) respectively, compared to control cells
treated with vehicle (Table 1). This cell growth inhibition was significantly enhanced to 80% and
90% by co-treatment of 1 µM sunitinib with 1 µM and 2.5 µM gemcitabine, compared to
gemcitabine alone (p<0.01) and sunitinib alone (p<0.01) and to control cells (p<0.0001) (Table
5.1).

Table 5.1: Inhibition of KCI-18 cell growth by sunitinib combined with gemcitabine in vitro.
KCI 18 cells were treated with gemcitabine at 1nM and 2.5 nM or sunitinib at 1 μM, or both
drugs in combination for 24 hrs, and then cells were plated in a colony formation assay for 10
days. The mean survival fraction was calculated from triplicate wells. *p<0.001;**p<0.0001.
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5.4.2 Therapeutic Response of Kidney Tumors by Combined Sunitinib and Gemcitabine in
Vivo
Using DCE-MRI and histological studies, we have previously demonstrated that
sunitinib, given at a dose of 20mg/kg/day for 7 days, caused trimming and regularization of
tumor vessels with improved tumor perfusion (Hillman et al., 2009). This dose was therefore
selected for combination with chemotherapy. To schedule administration of gemcitabine mice,
which had established kidney tumors [150 mm3 (SD 7), 186 mg (SD 4)] compared to normal
kidney sizes [125 mm3 (SD 2), 148 mg (SD 12)] on day 10 after tumor implantation, were treated
daily with sunitinib at 20mg/kg/day (SU20) for 3 days and then imaged by DCE-MRI (Figure 5.1
A). As observed in our previous studies, the IAUC distribution pattern of Gd uptake and
clearance in control mice was different for kidney tumors than for normal kidneys (Hillman et
al., 2009). Slower clearance of Gd was observed in the tumor-bearing kidney compared to faster
clearance in the normal kidney and the CIAUC curve for the tumor-bearing kidney showed a
pronounced shift to the right compared to normal kidney, indicative of a greater retention of Gd
(Figure 5.1A). In contrast, treatment with SU20 for 3 days showed identical patterns of Gd
uptake and clearance in the kidney tumor than in the normal kidney, as previously shown
(Hillman et al., 2009). IAUC and CIAUC histograms of the kidney tumor overlapped those of
the normal kidney and shifted to the left compared to control tumor kidneys, indicating
decreased Gd retention and improved tumor perfusion (Figure 5.1A). Based on these data
showing that vascular regularization is detectable by DCE-MRI after 3 days of daily treatment
with SU20, we designed the treatment schedule for combination therapy with gemcitabine as
presented in Figure 5.1B. Gemcitabine treatment was initiated at 3 days after pre-treatment with
SU20 for established KCI-18 kidney tumors. The schedule and dose of gemcitabine treatment
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were determined based on dose titration experiments. Following 3-5 injections of gemcitabine at
the dose of 50mg/kg, given two days apart together with daily SU20, a complete tumor growth
inhibition was observed, but this treatment was too toxic to the mice resulting in 50% death.
Therefore, we tested lower doses of 10, 20 and 40 mg/kg of gemcitabine (G10, G20, G40) given
twice a week, 3 days apart while SU20 was continued daily for the duration of the experiment
(Figure 5.1B). In separate experimental groups of 6-8 mice per group, the response to
gemcitabine treatment alone was compared to SU20 alone and both combined in a relatively
short-term experiment of 28 days, to compare tumor size at a time point when control tumors are
very large. The tumor-bearing right kidney and the normal left kidney were weighed and the
mean tumor weights were compared between each treatment group and control group (Figure
5.1C). Following SU20 treatment alone, kidney tumors were significantly smaller by 43%
compared to control mice tumors (p= 0.001); but these tumors were still large (Figure 5.1C), as
previously reported (Hillman et al., 2009). Compared to control, treatment with G10 caused
about 30% inhibition (p=0.04) and increased to 52.5% when combined with SU20 (p<0.001).
The effect of G20 was even greater causing 64% tumor growth inhibition (p<0.001) and 74%
when combined with SU20 (p<0.001) (Figure 5.1C). Although the difference in the mean tumor
weight of G20 + SU20 was not significant compared to G20 (p=0.33), the tumor weight data
(n=8) in the combined treatment was more consistent and less variable than with G20 only. The
average weight of tumor-bearing kidneys of mice treated with SU20 + G20 was only 223mg (SD
37) and their shape and size consistently looked closer to those of normal kidneys (166 mg, SD
22) with a mean difference of only 57 mg (Figure 5.1C). This combined therapy using
20mg/kg/day of sunitinib combined with four treatments of gemcitabine at 20mg/kg given 3 days
apart, for a total of 80mg/kg did not cause any signs of toxicity to the mice. However, when the
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dose of gemcitabine was increased to 40mg/kg, for a total of 160 mg alone or together with
SU20, it was associated with toxicity and weight loss. Treatment with G40 resulted in significant
tumor growth inhibition of 71% (p<0.001) when given alone but no further increase was
observed with combination with SU20 compared to G40 alone (p=0.53) (Figure 5.1C). The
difference between the G20 and G40 groups was not statistically significant (p=0.51). It should
be noted that the size of the normal contra-lateral kidneys was not affected by the single or
combined therapy at every dose of gemcitabine tested (Figure 5.1C, inset).
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Figure 5.1: KCI-18 kidney tumor response to sunitinib combined with gemcitabine. (A) DCEMRI of early vascular changes induced by sunitinib. Mice bearing established kidney tumors
were treated daily with sunitinib at 20mg/kg/day (SU20) for 3 days and imaged by DCE-MRI.
(B) Treatment schedule for combination therapy. Mice bearing established kidney tumors were
pre-treated with sunitinib at 20mg/kg/day (SU20) for 3 days on day 10-12 after KCI-18 cell
injection in the kidney. Then, mice received gemcitabine treatments at 10, 20 or 40 mg/kg given
3 days apart, twice a week for 2 weeks on days 13, 16, 20 and 23. Sunitinib was continued daily
for up to 28 days for a short-term experiment (2C) or for 50 days for a longer-term experiment
(2D). (C) Response of tumor-bearing kidneys to single and combined therapy. On day 28, tumorbearing kidneys and contralateral normal kidneys were resected and weighted. The weights of
the tumor-bearing kidneys and their median are reported for 6-8 mice per group treated with
vehicle (control) or sunitinib at 20mg/kg/day (SU20), or gemcitabine at 10 (G10), 20 (G20) or 40
(G40) mg/kg; each drug alone and in combination compared to the normal contralateral kidney
weights (NK). Inset shows weights of the normal contralateral kidneys for each treatment group.
*p<0.001. (D) Survival of KCI-18 kidney tumor-bearing mice treated with sunitinib combined
with gemcitabine. Mice bearing established kidney tumors were pre-treated with sunitinib (SU)
at 20mg/kg/day for 3 days on day 10-12 after KCI-18 cell injection in the kidney. Then, mice
received five gemcitabine (Gem) treatments at 20 mg/kg given 3-4 days apart, over 3 weeks on
days 13, 16, 20, 23 and 27 and sunitinib was continued daily, 5 days per week, for up to 50 days
as shown in Figure 5.2B. Mice were followed survival and Kaplan-Meier survival curves of
mice treated with vehicle (Con for control) sunitinib (SU) or gemcitabine (Gem) or both
combined (Gem+SU) were constructed.
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5.4.3 Survival of Kidney Tumor-Bearing Mice Treated with Combined Sunitinib and
Gemcitabine
From the experiments presented in Figure 5.1, we have determined the sequence,
schedule and doses for a safe and therapeutic combination of sunitinib and gemcitabine for
treating KCI-18 kidney tumor-bearing mice. We showed that a dose of sunitinib of 20mg/kg/day
combined with gemcitabine at 20mg/kg/treatment for 4 treatments result in optimal and
consistent tumor growth inhibition, when this effect was assessed on day 28 after tumor
implantation (Figure 5.1C). These conditions were selected to evaluate the effect of single and
combined therapies on mouse survival during a longer term experiment of 50 days. Mice bearing
established kidney tumors were pre-treated with 20mg/kg/day sunitinib for 3 days (day 10-12)
followed by four injections of gemcitabine at 20mg/kg given 3 days apart (days 13,16,20, 23)
following the same schedule shown in Figure 5.1B. An additional gemcitabine injection was
administred on day 23 because of the longer duration of the experiment. Sunitinib was continued
daily for 5 days a week for 6 weeks, up to day 50 (Figure 5.1B). Mice were monitored on a daily
basis and sick mice showing weight loss and/or limited mobility, as a result of large kidney
tumors, were euthanized, necropsied and the tumor weights were measured. Survival of animals
receiving sunitinib alone was not statistically different from control mice (p=0.08; median SU =
36 days; median controls = 29 days) (Figure 5.1D). In both groups, mice had large kidney tumors
at necropsy, the mean tumor weights of control mice was 1157 mg (SD 426) and that of
sunitinib treated mice was 675 (SD 226). Animals treated with gemcitabine alone for a total dose
of 100mg/kg had median survival of 43 days, significantly longer survival than controls
(p<0.001) and than the sunitinib group (p=0.009) but only 33% of the mice survived up to day
50. These mice had large tumors with mean weight of 794 mg (SD 338) when necropsied. The
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combination of sunitinib and gemcitabine resulted in longer survival compared to control mice
(p<0.001) and mice treated with sunitinib (p<0.001) but not significantly different from animals
treated with gemcitabine alone (p=0.13) (Figure 5.1D). Nevertheless, a higher proportion of 70%
of the mice (7/10) treated with the combined therapy survived by day 50 compared to 33% with
gemcitabine alone and 0% with sunitinib alone. Interestingly, these mice had large tumors with a
mean of 767 mg (SD 267), probably due to regrowth of kidney tumors which was not controlled
by maintenance therapy with sunitinib at 20mg/kg/day.

5.4.4 In situ Effects of Sunitinib and Gemcitabine on Kidney Tumors and Lung Metastases
Tumor-bearing kidneys and normal contralateral kidneys from mice treated with sunitinib
at 20mg/kg/day, gemcitabine at 20mg/kg and both combined were obtained on day 28 from
experiments described in Figure 5.1B, C. These tissues were processed for histology and H&E
staining. Kidney tumors from control mice presented as a high grade carcinoma, consisting of
tumor cells with large pleomorphic nuclei, prominent nucleoli, abundant eosinophilic cytoplasm
and large cytoplasmic inclusions (Hillman et al., 2004; Hillman et al., 2009). These tumors were
highly vascularized with a sinusoidal vascular pattern consisting of abnormal enlarged vessels
(Figure 5.2A). Focal extravasation of red blood cells (RBC) between tumor cells was observed
probably due to leakiness of vessels and disrupted basement membrane as previously reported
(Hillman et al., 2004; Hillman et al., 2009). Kidney tumors treated with sunitinib showed
considerable thinning, regularization and organization of tumor vessels with endothelial cells
lining the vessels (Figure 5.2A). A marked decrease in the number of tumor vessels was noted
(Figure 5.2A). These findings are consistent with our previous observations (Hillman et al.,
2009). Kidney tumors of mice treated with gemcitabine showed abnormal giant tumor cells
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exhibiting degenerative changes in their cytoplasm and nuclei, which were indicative of cell
death (Figure 5.2A). These giant cells, comprising about 70% of the tumor, contained
cytoplasmic vacuoles and pink eosinophilic inclusions and showed degenerative changes in
nuclei with focal karyopyknosis (Figure 5.2A). Compared to control tumors, the vascularity of
these gemcitabine-treated tumors was reduced and had lower numbers of enlarged vessels. A few
focal enlarged vessels were still observed along with few foci of RBC’s extravasation (Figure
5.2A). Kidney tumors treated with sunitinib and gemcitabine showed a higher frequency of about
90% abnormal giant tumor cells harboring the same cytoplasmic and nucleus degenerative
changes as those seen in gemcitabine alone (Figure 5.2A). The tumor vessels looked more
trimmed and more organized than those seen after gemcitabine treatment alone although focal
dilatation was still observed compared to sunitinib treated tumors. In lower magnifications, these
tumors looked like residual small nodules mostly consisting of giant tumor cells, which were
surrounded by normal epithelial renal cells (data not shown). The histology of tumors treated
with 40mg/kg of gemcitabine alone or with sunitinib was comparable to that shown in Figure
5.2A for tumors treated with 20mg/kg gemcitabine.
Tissue sections from the normal contralateral left kidneys (not implanted with tumor)
were also evaluated after single and combined sunitinib and gemcitabine treatments (Figure
5.2B). Normal kidneys from untreated control mice showed preserved kidney tissue architecture
with intact and regular blood vessels. As observed previously, sunitinib at 20 mg/kg/day caused
mild dilatation of a few vessels (Hillman et al., 2009). Interestingly, gemcitabine caused
dilatation of some of the vessels and mild focal extravasation of RBCs (Figure 5.2B). Following
combined sunitinib and gemcitabine treatment, focal areas of dilated vessels were seen but at a
lower frequency than with gemcitabine alone (Figure 5.2B).
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Figure 5.2: Histology of kidney tumors and normal kidneys from mice treated with sunitinib and
gemcitabine. Kidney tumors and normal contralateral kidneys from mice treated with sunitinib
(20mg/kg), gemcitabine (20mg/kg) and both combined, obtained on day 28 from experiments
described in Figure 5.1, were processed for histology and H&E staining. The main findings were
labeled on the prints with T for tumor, V for vessels, G for giant tumor cells. (A) Kidney tumors.
Control untreated tumors consisted of tumor cells with large pleomorphic nuclei, were highly
vascularized with a sinusoidal vascular pattern of abnormal enlarged dilated vessels with focal
extravasation of RBCs. Sunitinib (SU) treated tumors showed thinning and organization of tumor
vessels as well as a decrease in the numbers of tumor vessels. Kidney tumors of mice treated
with gemcitabine (Gem) contain numerous abnormal and giant tumor cells with cytoplasmic
vacuoles or eosinophilic inclusions and degenerative changes in nuclei with focal karyopyknosis.
Note some of the vessels in these tumors were still enlarged with foci of RBCs extravasation;
however to a lesser degree than in the untreated tumors. Tumors treated with sunitinib and
gemcitabine (SU + Gem) consisted mostly of abnormal degenerating giant tumor cells.
Trimming of tumor vessels was evident. (B) Normal contralateral left kidneys. The normal
kidney from control mice showed intact, regular and thin blood vessels. Sunitinib at 20mg/kg
showed a mild effect of dilatation in a few vessels. Gemcitabine caused dilatation of some of the
blood vessels. This effect was milder with combined sunitinib and gemcitabine with fewer
vessels dilated. All magnifications X40.
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Spontaneous metastasis to the lungs from primary KCI-18 kidney tumors has been
previously observed in this RCC metastatic model (Hillman et al., 2004). To assess the effect of
therapy on spontaneous lung metastases, lungs were resected on day 28 from kidney tumorbearing mice treated with sunitinib and gemcitabine and processed for H&E staining. In control
kidney-tumor bearing mice, all mice presented with metastatic lung tumor nodules showing the
typical morphology of KCI-18 RCC tumor cells with large pleomorphic nuclei and prominent
nucleoli (Figure 5.3). Areas of dilated vessels with extravasation of RBC’s were observed as
seen in primary kidney tumors (Figure 5.3). The average number of lung nodules was 26 per
mouse consisting of a mixture of large and small nodules. In sunitinib-treated mice, all mice had
metastatic lung nodules but the majority of the nodules were very small often containing less
than 10 cells per nodule and an average of 14 per mouse. The lung tumor nodules showed an
overall decrease in the number of tumor cells and/or areas of tumor destruction as well as a
marked decrease in vascularization (Figure 5.3). Mice treated with 20 or 40 mg of gemcitabine
had a lower frequency of lung nodules detectable in 3 out of 7 mice and presenting as 1-5 small
lung nodules per mouse. These lung tumor nodules exhibited giant tumor cells with cytoplasmic
vacuoles, eosinophilic inclusions and degenerative nuclei identical to those observed in primary
kidney tumors treated with gemcitabine (Figure 5.3). Few trimmed vessels were seen. The effect
of combined sunitinib and gemcitabine on metastatic lung nodules was more drastic with large
areas of hyalinization and fibrosis and few remaining giant tumor cells with degenerative
changes (Figure 5.3). Lung tumor nodules were detectable only in 3 out of 11 mice treated with
sunitinib combined with 20 or 40 mg/kg gemcitabine and the majority of these nodules were
very small often containing less than 5 cells per nodule and large areas of fibrosis.
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Figure 5.3: Histology of spontaneous lung metastases from mice treated with sunitinib and
gemcitabine. Lungs from mice treated with sunitinib (20mg/kg), gemcitabine (20mg/kg) and
both combined, obtained on day 28 from experiments described in Figure 5.1, were processed for
histology and H&E staining. The main findings were labeled on the prints with T for tumor, V
for vessels, G for giant tumor cells, F for fibrotic areas and L for normal lung alveoli. Metastastic
lung tumor nodules from untreated mice (Control) consisted of tumor cells with pleomorphic
nuclei and prominent nucleoli and contained areas of dilated vessels. Sunitinib (SU) –treated
mice had decreased number of tumor cells and vessels in lung tumor nodules. Lung tumor
nodules from gemcitabine (Gem) treated mice showed giant tumor cells with cytoplasmic
vacuoles and eosinophilic inclusions and decreased vascularization. Gemcitabine combined with
sunitinib (SU + Gem) contained large eosinophilic areas of hyalinization, fibrosis and a few giant
abnormal tumor cells. Figures were enlarged to show changes in lung tumor nodules.
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5.4.5 DCE-MRI Evaluation of Vascular Changes Induced by Gemcitabine Treatment in
Kidney Tumors
To monitor the effect of gemcitabine treatment by DCE-MRI, mice with established
kidney tumors were treated on day 13 with gemcitabine at a safe and therapeutic dose of dose of
20mg/kg, given 3-4 days apart, as determined from experiments described in Figure 5.1. Mice
were then tested by DCE-MRI after 1, 3 or 4 doses of gemcitabine (day 14, 18 and 21
respectively). For data analysis, the full kidney was selected as the ROI both for the right tumorbearing kidney and the left normal kidney (Figure 5.4A). As described above in Figure 5.1A, the
IAUC and CIAUC curves for the tumor-bearing kidney in control mice, showed a pronounced
shift to the right compared to normal kidney, indicative of a greater retention of Gd (Figure 5.4B,
C, D). Interestingly, gemcitabine treatment caused improved clearance of Gd in the tumor
bearing kidney compared to kidney tumors from control mice (Figure 5.4B). This was observed
by a shift of the IAUC and CIAUC curves towards those of normal kidneys (Figure 5.4C, D).
Furthermore, the patterns of Gd uptake and clearance were identical in the tumor-bearing kidney
and the normal kidney with IAUC and CIAUC curves overlapping, and thus indicative of
improved blood perfusion in the tumor (Figure 5.4). Gemcitabine also changed the pattern of
uptake and clearance in the normal kidney compared to the normal kidney of control mice,
showing a slower wash out of Gd (Figure 5.4B) and a wider IAUC distribution (Figure 5.4C).
These data suggest that gemcitabine is also causing vascular changes in the normal kidney. It
should be noted that vascular changes both in the kidney tumors and normal kidneys are
consistently observed with 1, 3 or 4 doses of gemcitabine. These findings suggest that one dose
of gemcitabine is sufficient to induce vascular changes which are reproducible with additional
treatments of gemcitabine.
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DCE-MRI parametric maps were derived from the C(t) curves for each pixel and
represent the total Gd uptake (AUC) for the tumor and surrounding kidney tissue (Figure 5.4E).
Parametric maps from control mice showed accumulation of Gd in the periphery of the tumor
with no uptake in the tumor core, indicative of poor tumor perfusion (Figure 5.4E), as previously
reported (Hillman et al., 2009). In the normal kidney of control mice, Gd uptake was distributed
in the entire kidney with a higher uptake in the medullary central area than in the peripheral
cortex, probably reflecting normal secretion of contrast agent (Figure 5.4E). Interestingly,
gemcitabine caused striking changes observed by parametric maps with uptake of Gd in the core
of the tumor, indicative of tumor perfusion (Figure 5.4E). The uptake of Gd in the tumor-bearing
kidney was similar to that seen in the normal kidney (Figure 5.4E). These data were consistently
reproduced following 1, 3 or 4 treatments of gemcitabine injections (Figure 5.4E).
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Figure 5.4: DCE-MRI imaging of vascular changes induced by gemcitabine in KCI-18 kidney
tumors. In separate experiments, mice bearing established kidney tumors were treated with
gemcitabine at 20mg/kg (Gem20) or with vehicle (control). Mice were imaged by DCE-MRI at
24 hrs following gemcitabine treatment after receiving either1 dose (Day 14), 3 doses (Day 18)
or 4 doses (Day 21), given 3 days apart. (A) T1 images: Baseline images prior to Gd contrast
agent injection. The full kidney was selected as the ROI for the tumor-bearing kidney (blue
contour on left of T1 image) and the contralateral normal kidney (red contour on right of T1
image). (B) C(t) kinetics of Gd contrast uptake and clearance: The first 10 time points represent
baseline data. Gd was injected at time point 10 and images were collected for 20 more time
points. (C) IAUC graphs: Data from the C(t) curves were compiled for 16 time points (112sec)
after Gd injection to draw IAUC112. The small black bar indicates the peak position of normal
kidney in control mice and can be used as a reference for curve shifting in normal kidneys and
kidney tumors treated with gemcitabine. (D) CIAUC graphs: CIAUC curves were derived from
IAUC curves. In A, B, C and D panels, blue lines are for kidney tumors and pink lines are for
normal kidneys. (E) AUC parametric map: Parametric color maps were constructed based on
uptake and concentration of Gd in the tissue, represented by the colors blue, green, yellow and
red with gradual increase of Gd from lowest values (blue) to highest values (red). The tumorbearing kidney is on the left and the normal contralateral kidney is on the right of the MR
images. The color coding in the kidneys are shown for integrated AUC. Data from a
representative mouse from each treatment group are presented.
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5.4.6 DCE-MRI of Kidney Tumors Treated with Sunitinib and Gemcitabine
The effect of sunitinib, gemcitabine and both combined on kinetics of Gd uptake and
clearance in tumors was evaluated by DCE-MRI. In this experiment, KCI-18 kidney tumorbearing mice were pre-treated daily with sunitinib at a dose of 20 mg/kg per day (SU20), for 3
days on days 10, 11, 12 after KCI-18 cell implantation in the right kidney. On day 13,
gemcitabine (GEM) was injected i.p. at 20 mg/kg, and this injection was repeated on day 15 and
day 17 while continuing daily treatment with SU20. After these 3 doses of gemcitabine, on day
18, mice were imaged by DCE-MRI as previously described (Hillman et al., 2009). For data
analysis, the full kidney was selected as the ROI both for the right tumor-bearing kidney and the
left normal kidney (Figure 5.5A). Analysis of the kinetics of uptake and clearance of Gd showed
that in control mice, the clearance of Gd in the tumor-bearing kidney was slow compared to
faster clearance in the normal kidney (Figure 5.5B, C, D). Following treatment with SU20, the
C(t) curves of the kidney tumors overlapped those of normal kidneys and showed similar uptake
and improved Gd clearance with much less Gd retention than that of kidney tumors in control
mice (Figure 5.5B). The tumor-bearing kidney IAUC curve looked more regular and shifted to
the left compared to control kidney tumors indicating decreased Gd retention (Figure 5.5C). Gd
uptake and clearance in the C(t) curves, IAUC and CIAUC showed identical patterns in the
tumor-bearing kidney compared to the normal kidney (Figure 5.5B, C, D). These findings are
consistent with our previous studies (Hillman et al., 2009) and suggest a return to more “normal
vasculature” with lower permeability (i.e., less leaky vessels). Following treatment with
gemcitabine, the vascular changes described in Figure 5.4 were reproduced in this experiment,
including improved clearance of Gd in the tumor bearing kidney, and slower clearance of Gd in
the normal kidney (Figure 5.5B, C, D). Following combined therapy of SU20 with gemcitabine,
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the patterns of Gd uptake and clearance resembled those of gemcitabine alone both in kidney
tumors and normal kidneys with a tendency to decreased clearance of Gd (Figure 5.5B, C, D). As
observed for SU20 alone, the IAUC and CIAUC curves of kidney tumor and normal kidney
overlapped and showed a pattern close to that of normal kidney in control mice (Figure 5.5C, D).
DCE-MRI parametric maps were derived from the C(t) curves for each pixel and
represent the total Gd uptake (AUC) for the tumor and surrounding kidney tissue (Figure 5.5E).
As described for Figure 5.4, parametric maps from control mice consistently showed
accumulation of Gd in the periphery of the tumor with no uptake in the tumor core, indicative of
poor tumor perfusion (Figure 5.5E). Parametric maps of SU20 treated mice showed a significant
accumulation of Gd in the tumor-bearing kidney including Gd uptake in the tumor and also Gd
accumulation in the normal kidney (Figure 5.5E), as shown previously (Hillman et al., 2009).
Gemcitabine caused striking changes observed by parametric maps with tumor perfusion and an
uptake of Gd similar to normal kidney (Figure 5.5E), as shown in separate experiments in Figure
5.4E. These findings were reproduced with the combined SU20 and gemcitabine including tumor
perfusion but less Gd accumulation than that seen with SU20 alone (Figure 5.5E).
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Figure 5.5: DCE-MRI imaging of vascular changes induced by gemcitabine and sunitinib in
KCI-18 kidney tumors. Separate experimental groups of 3 mice per group were treated with
vehicle only (control), or sunitinib only (SU20) or gemcitabine only (Gem20) or sunitinib +
gemcitabine (SU20+Gem20). Mice bearing established kidney tumors were pre-treated with
sunitinib at 20mg/kg/day (SU20) for 3 days on day 10-12 after KCI-18 cell injection in the
kidney. Then, mice received three gemcitabine treatments at 20 mg/kg (Gem20) given on days
13, 15 and 17 while continuing daily sunitinib treatments. At 24 hrs after the last gemcitabine
treatment (day 18), mice were imaged by DCE-MRI for 30 time points at 7 sec intervals. (A) T1
images: Baseline images prior to Gd contrast agent injection. The full kidney was selected as the
ROI for the tumor-bearing kidney (blue contour on left of T1 image) and the contralateral normal
kidney (red contour on right of T1 image). (B) C(t) kinetics of Gd contrast uptake and clearance:
The first 10 time points represent baseline data. Gd was injected at time point 10 and images
were collected for 20 more time points. (C) IAUC graphs: Data from the C(t) curves were
compiled for 16 time points (112sec) after Gd injection to draw IAUC112. The small black bar
indicates the peak position of normal kidney in control mice and can be used as a reference for
curve shifting in normal kidneys and kidney tumors following treatment. (D) CIAUC graphs:
CIAUC graphs were derived from IAUC curves. In B, C and D graphs, blue lines are for kidney
tumors and pink lines are for normal kidneys. Data from a representative mouse from each
treatment group are presented. (E) AUC parametric map: Parametric color maps were
constructed based on uptake and concentration of Gd in the tissue, represented by the colors
blue, green, yellow and red with gradual increase of Gd from lowest values (blue) to highest
values (red). The tumor-bearing kidney is on the left and the normal contralateral kidney is on
the right of the MR images. The color coding in the kidneys are shown for integrated AUC.
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5.4.7 DCE-MRI Quantitation of Vascular Changes of Kidney Tumors Treated with
Sunitinib and Gemcitabine
To quantitate the vascular changes induced by sunitinib and gemcitabine and study the
reproducibility of our findings, R50 values for 5 mice per treatment group were derived from
CIAUC curves for both kidney tumors and normal kidneys (Hillman et al., 2009). The R50
(median) values correspond to the concentration of Gd at which 50% of the pixels have been
included (Figure 5.6A) (Hillman et al., 2009). Lower R50 values were consistently observed in
mice treated with SU20, gemcitabine and both combined compared to control mice for kidney
tumors (Figure 5.6B). Compared to R50 values of normal kidneys in control mice, a trend to
lower R50 was also observed for normal kidneys suggesting a mild systemic effect of both drugs
affecting blood flow (Figure 5.6C). To compare the vascular changes induced by the drugs in
kidney tumors to those induced in normal kidneys, R50 values of kidney tumors were
normalized to the R50 values of normal contralateral kidneys for each mouse (NR50 KT v/s NK)
(Figure 5.6D) (Hillman et al., 2009). These values were consistently much smaller in mice
treated with each drug and both combined compared to control mice (Figure 5.6D).
Normalization of R50 values of treated kidney tumors versus control kidney tumors (NR50
KTtreat v/s KTcont) showed negative values with each drug alone and both combined (Figure
5.6E). To assess the effect of SU20 and gemcitabine on normal contralateral kidneys, R50 of
normal kidneys from treated mice were normalized to normal kidneys from control mice (Figure
5.6F). These NR50 data of normal kidneys showed also negative values for mice treated with
each drug separately and both combined (Figure 5.6F) but less than those of NR50 KTtreat v/s
KTcont. These data indicate a relatively mild effect by either drug alone and combined on normal
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kidney vasculature (Figure 5.6F) in contrast to a more pronounced effect on vasculature of
kidney tumors (Figure 5.6E).

Figure 5.6: R50 quantitation of DCE-MRI data of KCI-18 kidney tumors. Mice were treated with
vehicle (control, Con), sunitinib at 20mg/kg/day (SU), gemcitabine at 20 mg/kg (Gem) or both
sunitinib and gemcitabine, and then imaged by DCE-MRI as described in Figure 5.5. Data
obtained from MRI images were quantitated. (A) R50 value calculation: The R50 value is
derived from CIAUC curves (as shown for control mouse) and corresponds to the Gd
concentration at which 50% of the pixels have been included. (B) Tumor-bearing kidney R50:
R50 of kidney tumors from 5 mice per treatment group. (C) Normal kidney R50: R50 normal
contralateral kidney for each mouse shown in B. (D) NR50 of KT vs NK: NR50 represents
normalization of R50 values of kidney tumors (KT) relative to R50 values of normal
contralateral kidney (NK) calculated as [R50KT - R50NK] / R50NK for each mouse. (E) NR50 of
KTTREAT vs KTCONT: Normalization of R50 values of kidney tumors from treated mice (KTTREAT)
relative to the mean R50 values of kidney tumors from control mice (KTCONT) calculated as [R50
KTTREAT– R50 KT mean cont] / R50 KT mean cont for each mouse. (F) NR50 of NKTREAT vs NKCONT:
Normalization of R50 values of normal kidneys of treated mice relative to the mean R50 values
of normal kidneys from control mice calculated as [R50 NKTREAT – R50 NK mean cont] / R50 NK
mean cont for each mouse. Data are presented for 5 mice per treatment group in each panel.
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5.5 Discussion
The concept of normalization of tumor vessel via elimination of excess endothelial cells
to improve the blood flow, reduce vessel leakiness, interstitial pressure and increase drug
delivery to tumor cells, has shown promise for combination with anti-cancer drugs [37-39]. We
have previously determined the doses and schedule of the anti-angiogenic drug sunitinib which
cause thinning and regularization of tumor vessels in kidney tumors of the KCI-18 RCC
orthotopic tumor model in nude mice (Hillman et al., 2009). We found that daily treatment with
20mg/kg/day of sunitinib caused better tumor perfusion and decreased vascular permeability by
DCE-MRI (Hillman et al., 2009). These observations on vascular changes were in agreement
with in situ histological studies demonstrating thinning and regularization of tumor vessels
(Hillman et al., 2009). In addition, this dose caused only mild changes in vessels in normal
kidney tissue and was not toxic to the mice (Hillman et al., 2009). Based on these findings, the
dose of 20mg/kg/day of sunitinib was selected to regularize the blood flow in the tumor and then
schedule chemotherapy with gemcitabine. The conditions for combining anti-angiogenic therapy
with chemotherapy were investigated.
Dose searching studies using 10, 20 or 40 mg/kg of gemcitabine showed that a schedule
of injections given 3 days apart was less toxic than every two days. Doses of 20 and 40 mg/kg
gemcitabine were more effective than 10 mg/kg and caused significant kidney tumor growth
inhibition. To schedule the combination of gemcitabine with sunitinib, regularization of tumor
vessels was monitored by DCE-MRI of kidney-tumor bearing mice treated with sunitinib only.
DCE-MRI showed that one day sunitinib treatment at a dose of 20mg/kg/day was not sufficient
to induce regularization of vasculature and resulted only in minor vascular changes (Hillman,
personal communications). However, DCE-MRI of mice treated for 3 days with 20mg/kg/day
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sunitinib confirmed that this schedule was sufficient to induce vascular changes of decreased Gd
retention and improved tumor perfusion in KCI-18 kidney tumors, indicating normalization of
blood vessels. Therefore, gemcitabine treatment was initiated after 3 consecutive daily
treatments of sunitinib. When gemcitabine was administered after sunitinib and given at a dose
of 20 mg/kg for four treatments, while continuing daily administration of sunitinib, the effect of
the combined therapy was particularly effective causing about 74% reduction in tumor weight by
day 28. This schedule and dosage of sunitinib given in conjunction with gemcitabine were well
tolerated by the mice and were not associated with toxicity. This combined therapy significantly
inhibited the growth of the tumor in the kidney and this effect was consistent in all mice tested in
contrast to greater variability from mouse to mouse with each modality alone. The size and shape
of the tumor-bearing kidneys were comparable to those of the normal contralateral kidneys. In
agreement with our gross observations, only small residual tumor nodules surrounded by normal
kidney tissue were histologically observed. Tumors treated with gemcitabine alone or both
gemcitabine and sunitinib showed a high frequency of abnormal giant tumor cells with
degenerative changes in their cytoplasm and nuclei, indicative of processes of cell death. Similar
effects of the single and combined modalities were also observed histologically in the
spontaneous lung metastases. In lungs of sunitinib-treated mice, the tumor nodules showed a
decrease in size, cellularity and vascularization, probably as a result of the anti-angiogenic
activity of sunitinib. Gemcitabine treatment caused a marked increase in giant tumor cells with
degenerative processes in metastatic lung nodules, which looked identical to those observed in
primary kidney tumors. This effect was more pronounced in lung tumor nodules treated with the
combined therapy, as visualized by few remaining giant tumor cells surrounded by fibrotic areas.
The frequency and size of metastatic lung tumor nodules were drastically reduced by
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gemcitabine alone or combined with sunitinib compared to control mice.

These findings

observed in spontaneous lung metastases suggest that sunitinib and gemcitabine act systemically
affecting both the primary and metastatic tumors and therefore a combined approach of antiangiogenic drug and chemotherapy drug could be effective for metastatic RCC disease.
Long-term survival studies, using a schedule of 3 days of 20mg/kg of sunitinib followed
by five treatments of 20mg/kg of gemcitabine and continued daily administration of sunitinib
resulted in a significant increase in mouse survival. Interestingly, even though sunitinib daily
treatment was continued after gemcitabine therapy, kidney tumors recurred as observed by day
50. These data suggest that 20mg/kg of sunitinib was not sufficient to maintain the initial
dramatic inhibition of tumor growth induced by gemcitabine and prevent regrowth of tumor
vessels. It should be noted that the total dose of gemcitabine ( 100-120mg/kg) used in our study
is much lower than that used in pancreatic cancer pre-clinical models (480mg/kg) (Bocci G et al.,
2004). This low dose of gemcitabine in our RCC pre-clinical model is very effective when
combined with an anti-angiogenic drug as shown in the pancreatic cancer model (Bocci G et al.,
2004). These data also demonstrate that DCE-MRI is a useful means to monitor early vascular
changes induced by sunitinib to assess improved blood flow and schedule initiation of
chemotherapy. Recent clinical studies have successfully shown that early changes in DCE-MRI
of cancer patients have the potential to predict response and guide therapy (Ah-See et al., 2008;
Craciunescu et al., 2009; Galban et al., 2009).
Our previous observations of uptake and clearance of Gd in control kidney tumors
monitored by DCE-MRI were confirmed in the current study (Hillman et al., 2009). These
patterns included slow clearance of Gd and accumulation of Gd in the periphery of the tumor
with no uptake in the tumor core, as seen in parametric maps. These findings suggested poor
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tumor perfusion, probably as a result of leakiness from abnormal enlarged tumor vessels as
observed by histology of tumor sections and extravasation of RBC’s (Hillman et al., 2009).
Imaging of kidney tumor-bearing mice treated with gemcitabine by DCE-MRI revealed that
gemcitabine caused vascular changes both in the tumors and in normal kidneys. Kidney tumors
treated with gemcitabine showed improved clearance of the Gd contrast agent relative to the
normal contralateral kidney. Increased tumor perfusion caused by gemcitabine was also observed
by parametric maps showing uptake of Gd in the core of the tumor in contrast (Hillman et al.,
2009). Histologically, gemcitabine-treated tumors showed a decrease in the number of enlarged
vessels compared to control tumors. These findings on improved tumor perfusion associated with
trimming of the enlarged vessels of the kidney tumors suggest that gemcitabine also exerted
cytotoxic activity on endothelial cells. In agreement with our findings, recent studies
demonstrated that endothelial cells are indeed destroyed by gemcitabine both in vitro and in vivo
in an orthotopic pre-clinical model of pancreatic cancer (Laquente et al., 2008). These studies
and our findings indicate that the mode of action of gemcitabine includes both cytotoxicity to
tumor cells but also an anti-angiogenic effect, thus acting as well on the tumor microenvironment
as shown for sunitinib (Laquente et al., 2008).
Consistent with our previous studies, sunitinib treatment of kidney tumors with 20mg/kg
showed patterns of uptake and improved Gd clearance by DCE-MRI, comparable to those of
normal kidneys, suggesting a return to more “normal vasculature” with lower permeability (i.e.,
less leaky vessels) (Hillman et al., 2009). Histologically, kidney tumors treated with sunitinib
showed considerable thinning, regularization and organization of tumor vessels, as previously
reported (Hillman et al., 2009). Combination of sunitinib and gemcitabine, the patterns of Gd
uptake and clearance resembled those of gemcitabine alone both in kidney tumors and normal
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kidneys with a tendency to decreased clearance of Gd. Parametric maps showed increased tumor
perfusion. These data were in agreement with in situ histological findings showing tumor vessels
looking more trimmed and organized than those seen after gemcitabine treatment alone.
Quantitation of vascular changes induced by sunitinib and gemcitabine confirmed the
reproducibility of our findings. Lower R50 values were consistently observed in mice treated
with SU20, gemcitabine and both combined compared to control mice for kidney tumors. A
trend to lower R50 values was also observed for normal kidneys in treated mice relative to
control mice. These findings were corroborated by in situ histological observation of dilatation of
some of the vessels in normal kidney tissue sections. These data indicate a relatively mild
systemic effect on normal kidney vasculature mediated by either drug alone and both drugs
combined. This is in contrast to a more pronounced effect of the therapy on kidney tumor
vasculature resulting in increased tumor perfusion and decreased vascular permeability.
Our data suggest that both sunitinib and gemcitabine exert anti-angiogenic effects in
addition to their cytotoxic anti-tumor activity. These effects on both the tumor vasculature and
tumor cells were observed both in primary kidney tumors and spontaneous lung metastases
indicating that a combined approach of anti-angiogenic drug and gemcitabine could be effective
for metastatic RCC disease. These studies also emphasize the clinical potential of using DCEMRI to select the dose and schedule of anti-angiogenic drugs to schedule chemotherapy and
improve its efficacy.
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6.1 Abstract:
Purpose: To develop new dynamic contrast enhanced (DCE) magnetic resonance imaging
(MRI) parameters to quantify the vascular effects of different doses of the antiangiogenic drug
sunitinib on renal cell carcinoma (RCC) kidney tumors in mice.

Materials and Methods: Mice bearing established RCC xenograft tumors were treated with
sunitinib doses of 10, 20 or 40 mg/kg/day respectively (SU10, SU20 or SU40) or treated with
vehicle only (control). New DCE parameters, including fraction of active pixels (FAP), contrast
agent uptake to the peak (AUCtp), time to peak concentration (TTP), washout slope (Nslope) and
full width half maximum (FWHM) were obtained from T1-weighted images. These parameters,
as well as more conventional measures, were quantified for tumor-bearing kidneys and normal
kidneys.

Results: Treatments with SU20 and SU40 caused increased perfusion in the tumor core
compared to control and SU10. Kidney tumors treated with SU20 had an almost identical pattern
of contrast agent uptake rate, peak and clearance as those observed in normal kidneys. The effect
of SU20 on normal kidneys was milder than that observed with SU40. Treatment with SU40
caused increased contrast agent uptake by the cortex of the normal kidneys compared to the
normal kidneys in control and SU10. FWHM also provided new information about the effect of
different treatment doses and showed that kidney tumors treated with SU20 have almost the
same values of FWHM as the normal kidneys in control mice. The other measures also painted a
consistent picture of the treatment effect on the vascular system.
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Conclusion: The new DCE parameters, including FAP, AUCtp, Nslope and FWHM have the
potential to give a precise description of the treatment effect not only in the whole mouse kidney
but also in different regions inside the kidney. The results of this work should enhance the
reproducibility of DCE results.
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6.2 Introduction:
Numerous clinical studies have used dynamic contrast enhanced (DCE) magnetic
resonance imaging (MRI) as a non-invasive method to diagnose lesions of different types
(Huang et al., 2004; Ng et al., 2010), to grade lesions (Asaumi et al., 2003; Ludemann et al.,
2005; Bhooshan et al., 2010) and to evaluate drug effectiveness on tumor vascular characteristics
(Hayes et al., 2002; Haris et al., 2008). Many of these studies have shown that DCE is a valuable
tool to study tissue perfusion. DCE-MRI uses gadolinium diethylenetriamine penta-acetic acid
(Gd-DTPA) as a contrast agent injected into the blood stream. Gd is assumed to be well mixed
with the blood and travels through the major vessels and capillaries. The perfusion of the tissue
can be assessed using dynamic T1-weighted images since Gd shortens the T1 value of the blood.
Signal enhancement depends on the concentration of Gd in the blood. The kinetics of the
changes in signal intensity before, during and after Gd injection, for a region of interest (ROI),
indirectly provides Gd concentration in that ROI (Knopp et al., 2001). However, Gd
concentration, in any selected ROI, depends on tissue hemodynamic parameters and vasculature
(Tofts and Kermode, 1991; Preda et al., 2006; Yabuuchi et al., 2008). In tumors, Gd leaks from
abnormal vessels into extracellular space. The number of blood vessels in tumors and the transendothelial permeability of the vessels are often higher than the ones in normal tissue. Hence,
more signal enhancement will occur in tumors. The role of DCE-MRI is to measure these
hemodynamic parameters to help differentiate between normal and malignant tissues (Preda et
al., 2006; Van Cann et al., 2008).
The assessment of tissue hemodynamic characteristics can be executed by semiquantitative or quantitative methods (Galbraith et al., 2002; Yankeelov and Gore, 2009). Semiquantitative methods include histogram analysis of Gd uptake and washout and parametric maps.
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These evaluations depend on many factors such as Gd injection, hardware settings, sequence
choice and systemic changes in the blood circulation (Galbraith et al., 2002). On the other hand,
quantitative methods are independent of these factors. In these methods, DCE data can be fitted
to a pharmacokinetic model to estimate values for vessel wall permeability, vessel surface area,
volume fraction of vascular plasma and the volume fraction of extracellular extravascular space
(EES) (Murase, 2004; Yankeelov and Gore, 2009). Among other models, Toft’s model is often
used to produce Ktrans (which represents the product of the capillary wall permeability and
surface area per unit volume), ve (volume of the extravascular extracellular space (EES)) and
EES maps (Tofts and Kermode, 1991; Tofts et al., 1995; Guo and Reddick, 2009). Nevertheless,
DCE quantification is not easy, and these quantitative methods require an accurate arterial input
function (AIF) and a pharmacokinetic model for data fitting (Yang et al., 2004; Cutajar et al.,
2009).
Renal cell carcinoma (RCC) develops in the kidney and metastasizes to other organs,
most particularly the lungs (Whang and Godley, 2003). The vascular endothelial growth factor
(VEGF) is a key growth factor in the angiogenic process, which promotes the proliferation,
migration, and invasion of endothelial cells and plays a role in vascular permeability. Sunitinib
is an antiangiogenic drug which has recently shown a significant therapeutic effect (van
Spronsen et al., 2005; Rini, 2009). It has been found to inhibit tumor growth by selective
inhibition of the VEGF receptors and platelet-derived growth factor causing apoptosis in both
tumor microvessels and in the tumor cells (Patard et al., 2006; Billemont et al., 2007; Papaetis et
al., 2008; Sawhney and Kabbinavar, 2008; Gan et al., 2009). This treatment can deprive the
tumor cells of nutrients, and hence inhibit its growth. However, higher doses of sunitinib, which
cause complete destruction of tumor blood vessels, can also affect the normal vasculature of vital
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organs such as the heart, and could cause the blood vessels to leak more (Gan et al., 2009). These
high doses of sunitinib could also alter blood flow and oxygen delivery to the tumor affecting the
efficacy of combining this treatment with either chemotherapy or radiotherapy. In the current
study, we report the development of four new DCE parameters that characterize the behavior of
Gd uptake with time. The new proposed parameters were calculated from the DCE data of a
preclinical model of the human RCC KCI-18 cell line implanted in the right kidney of immune
deficient nude mice (Hillman et al., 2009). Mice bearing established KCL-18 kidney tumors
were treated with different doses of sunitinib. Vascular changes induced by the drug were
analyzed by DCE-MRI. We previously reported DCE-MRI studies in this model, in which we
presented the parameters of the initial area under the curve (IAUC), the cumulative initial area
under the curve (CIAUC) graphs and the R50 (median) value that represents the concentration of
Gd at which 50% of the pixels have been included (Hillman et al., 2009). These DCE-MRI data
were further analyzed by evaluating four new DCE parameters, including blood volume
estimates, washout slope, fraction of active pixels as well as the full width at half maximum
(FWHM). These parameters were compared to more conventional measures.
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6.3 Materials and Methods:
6.3.1 KCI-18/IK RCC Tumor Model:
A preclinical model of RCC was established by implantation of Karmanos Cancer
Institute-18 (KCI-18) human papillary RCC cell lines in the right kidney of immune deficient
nude mice. Mice were housed and handled under sterile conditions in facilities accredited by the
American Association for the Accreditation of Laboratory Animal Care. The animal protocol
was approved by the Wayne State University Animal Investigation Committee. A few mice were
killed at an early time point to assure tumor growth before initiating the treatment. By days 10 to
12, after KCI-18 cell injection, mice were treated with sunitinib (Pfizer, Inc, New York, NY).
Sunitinib treatment was prepared in a carboxymethyl cellulose suspension vehicle. Mice were
divided into four groups: three groups were treated with sunitinib at different doses of 10, 20, or
40 mg/kg/day (SU10, SU20, or SU40, respectively), and the fourth group was treated with
vehicle only (control mice). Sunitinib treatment were given orally by gavage on a daily basis for
7 days, and then mice were imaged by DCE-MRI, as previously detailed (Hillman et al., 2009).

6.3.2 MR Imaging:
Mice were anesthetized by intraperitoneal injections of 0.35 ml pentobarbital and 0.35ml
ketamine at a concentration of 52.5mg/kg. A catheter was then inserted into their tail vein, which
was attached to a syringe containing Gd-DTPA contrast agent (Berlex, Wayne, NJ). Mice were
positioned on a cradle heated by temperature-controlled water and were given a second low dose
of anesthetics of 15mg/kg each in 0.1ml to avoid motion problems while scanning the animal in
the magnet. A 2-cm diameter receive-only surface coil was placed over the tumor, and the cradle
was placed inside an 11-cm inner diameter transmit-only volume coil. MR imaging was
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performed in the MR Research Facility at Wayne State University, using a Bruker Biospec
AVANCE animal scanner (Bruker, Karlsruhe, Germany) equipped with a 4.7-T horizontal bore
magnet and actively shielded. Anatomical imaging was done using a 2D T2-weighted spin echo
scan (TR = 2000ms, TE = 52.4ms) to get an overview of the kidney. The DCE-MRI images
were collected at 30 time points (7 sec between time points) with the following parameters: 5
slices, TR = 54.7 ms, TE = 2.9 ms, two flip angles 5 and 30 degrees, FOV = 32mm x 32mm,
slice thickness = 1.5mm with 0.5 mm gap and matrix = 128x128. The contrast agent dose was
0.1mmol/kg of body weight Gd-DTPA (Magnevist, Berlex Laboratories, Wayne, NJ) and was
injected at time point 10 into the tail vein catheter. Then, images were acquired for 20 more time
points. All DCE data analysis was done using our homemade software SPIN (signal processing
in NMR, Detroit, MI) (Haacke et al., 2007).

6.3.3 DCE Theory:
The changes in the DCE signal with time, S(t), for a given flip angle, can be obtained from the
FLASH equation
S θ (t ) =

ρ 0 sin θ (1 −e −TR / T 1(t ) )
(1 − e −TR / T 1(t ) cos θ )

[5.1]

where ρ 0 is the spin density, θ is the flip angle and TR is the repetition time. For a given TR,
T1(t) can be calculated from the equation above. Knowing T1(t) and using a fixed T1(0) equal to
1000 ms (Haacke et al., 2007), the concentration of Gd with time can be calculated from
C (t ) =

1  1
1 
*
−
a  T 1(t ) T 1(0) 

[5.2]

where “ a ” is the proportionality constant referred to as the longitudinal or T1 relaxivity with
units of (mM)-1s-1, and it is a property specific to the composition of Gd.
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Once C(t) is known , IAUC is calculated from
t2

IAUC = ∑ C (t )∆t

[5.3]

t1

where t1 and t2 are user defined time points. CIAUC (which represents the cumulative number of
pixels counted within an ROI that corresponds to a given contrast agent uptake (IAUCi for (0 ≤ i
≤ N bins) in a given ROI) and normalized to the total number of pixels), is calculated from
m

CIAUC (m) =

∑ n( IAUC )
i =1
N

i

∑ n( IAUC )
i =1

[5.4]

i

where N is the last bin or maximum IAUC and n(IAUCi) is the number of pixels with a value of
the IAUC bin.
The R50 value was defined as the concentration of Gd at which CIAUC(m) = 50%, i.e.,
the median of the CIAUC histogram, and NR50 is defined as the normalized value of R50 as
NR50 = ( R50 tumor − R50 normal ) / R50 normal

[5.5]

6.3.4 DCE Data Thresholding and Fraction of Active Pixel Determination:
The drug effectiveness in semi-quantitative DCE-MRI analysis depends on the change of
Gd uptake. A tumor might be composed of either cells which are alive or dead (necrotic)
(Karahaliou et al., 2010). A set of subtracted images is created by subtracting a set of DCE
images of a given time point after Gd injection from a set of DCE images of a time point before
Gd injection. These images can help us differentiate between active or necrotic vascular areas of
the tumor. Applying a threshold to the original DCE images and to the subtracted series is used
to suppress pixels that are just noise or have no signal enhancement. The threshold value was
estimated from the image background noise. The pixels excluded from dynamic DCE image
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thresholding represent the noise pixels whereas the pixels excluded from subtracted images
represent the no signal enhancement pixels (i.e., necrotic part of the tumor). As a further measure
of interest, we define the fraction of active pixels (FAP) as the number of active pixels (i.e., the
remaining pixels after applying the threshold) normalized to the total number of pixels in the
ROI.

6.3.5 DCE Parametric Maps: New Parameters AUCtp and TTP:
The concentration time dependence, C(t), will vary according to the tissue hemodynamic
properties. Given a general rise and fall of C(t), we calculate 6 different DCE parametric maps
for each pixel in the image. These include the total Gd uptake (AUC), the rate of uptake (Pslope),
the peak concentration (PEAK), the uptake to the peak (AUCtp), the time to peak concentration
(TTP) and the clearance or washout slope of Gd (Nslope). Figure 6.1 shows the C(t) curve and
the time points (ti, tpeak, tns,

tend)

that were used to calculate the DCE parametric maps. The

definitions for these measures are given by
t end

AUC = ∑ C(t) • ∆t

[5.6]

Pslope = (C(t peak ) − C (t i )) /( t peak − t i )

[5.7]

PEAK = C peak = Max(C(t ))

[5.8]

ti

t peak

AUCtp =

∑ C(t) • ∆t

[5.9]

ti

TTP = t(C peak ) = t peak

[5.10]

and
Nslope = (C(t ns ) − C(t peak )) /( t ns − t peak )

[5.11]
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where ti is the Gd injection time point at which C(ti)-C(ti+1)> 2SD, tpeak is the time at the
concentration peaks, tns is the time point at which (C(tpeak)-C(tns))/(tpeak-tns) > (C(tpeak)C(tend))/(tpeak-tend), and tend is the last acquired time point. C(ti) is Gd concentration at the injection
time point, C(tpeak) is Gd concentration at the peak, C(tns) Gd concentration at tns, and finally
C(tend) is Gd concentration at the last acquired time point (Figure 6.1). AUC is defined the same
as IAUC except that it is integrated from the injection time point (ti) to the last acquired time
point (tend) where IAUC is integrated to a user defined time points (t1 and t2).

C(t) graphs

C(t) values

C(tpeak)

C(tns)
C(tend)

C(ti)
ti

tpeak tns

tend

Time points
Figure 6.1: Kinetics of Gd uptake are represented in C(t) curves showing Gd injected at ti time
point, peak of Gd uptake (tpeak), the time point at which (C(tpeak)-C(tns))/(tpeak-tns) > (C(tpeak)C(tend))/(tpeak-tend) (tns) and the last time point (tend) at which images were acquired. C(ti) is Gd
concentration at the injection time point, C(tpeak) is Gd concentration at the peak, C(tns) Gd
concentration at tns, and finally C(tend) is Gd concentration at the last acquired time point. The
DCE parametric maps are obtained from C(t) curves.
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In the case where there is no extravasation of the contrast agent prior to tpeak, AUCtp can
be used as a measure of the blood volume fraction (λ) as follows:
t peak

∑C

AUCtptissue
t
λ=
= t peaki
AUCtpblood

tissue

(t ) ⋅ ∆t

∑ Cblood (t ) ⋅ ∆t

[5.12]

ti

where AUCtp for tissue has been normalized to AUCtp for blood.

6.3.6 Full Width at Half Maximum (FWHM)
Another potential characteristic measure is the full width at half maximum (FWHM),
which represents how fast the contrast agent is washed out across all pixels. FWHM is thought to
be more resilient to the effects of contrast agent leakage. In order to calculate the FHWM, the
IAUC data should be filtered to reduce noise using a direct form transposed II digital filter. This
filter contains implementation of the standard difference equation.
After filtering IAUC data, FWHM is found from the difference between the two halfmaximum points:
FWHM = x 2 - x1

[5.13]

where x2 and x1 represent the two half maximum times at which IAUC(x2) =IAUC(x1) as
shown in Figure 6.2.
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Figure 6.2: Determination of full width at half maximum (FWHM). For each mouse included in
the study, IAUC data was filtered to reduce noise using an averaging filter. The maximum value
of the IAUC histogram was found. FWHM is calculated from the difference between the two
half-maximum points x1 and x2.
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6.4 Results:
6.4.1 Threshold of Data Images and Assessments of FAP
The original DCE and subtracted images were used to draw two ROIs on both the right
tumor-bearing kidney and the left normal kidney (Figure 6.3-a and 6.3-b). The necrotic area or
poorly vascularized part of the tumor appears as a black area in the subtracted images. These
pixels (i.e., necrotic part of the tumor) are thresholded out of C(t) to be processed since they shift
the CIAUC curves to the left indicating less Gd uptake (Figure 6.3-d). The simplest and currently
most effective means to threshold DCE images is to set the signal intensity for the pixel whose
intensity falls out of a certain range to zero and exclude these pixels from further quantification.
Using a fixed T1(0)= 1000ms, threshold= 20 (measured from background noise of the original
DCE image), the concentration of Gd-DTPA, C(t), uptake in both kidneys was calculated over
time. The IAUC and CIAUC graphs were integrated over 16 time points (112 sec) after GdDTPA injection. The resulting, un-thresholded IAUC has a bimodal distribution (Figure 6.3-c)
and hence shifts the CIAUC curve more to the left (Figure 6.3-d). However, after applying the
threshold, the IAUC is more Gaussian distributed (Figure 6.3-e), and the resulting CIAUC is
shifted back to the right compared to the CIAUC curve before applying the threshold (Figure
6.3-f). This better indicates Gd uptake in active tissue. FAP values were calculated for all the
cases. In general, FAP values for the normal kidneys are higher than the FAP values in the
kidney tumor due to the presence of necrotic areas in the tumor (Table 6.1). R50 values after
applying the threshold are larger than R50 values before applying the threshold (Figure 6.4-a and
6.4-b). However, one could notice that the changes in R50 values before and after applying the
threshold follow the same trend in normal kidneys where as it varies in kidney tumors.
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Figure 6.3: Threshold application to DCE-MRI images. Two ROI were plotted on the right tumor
bearing kidney and the left normal kidney as shown in a) Dynamic DCE image, and b)
Subtracted image. c) IAUC and d) CIAUC graphs before applying the threshold, IAUC graph
shows a bimodal behavior resulting from noise, necrotic and active parts of the tumor (i.e., the
selected ROI shown in b) leading to a false shift in the CIAUC graphs and smaller R50 values. e)
IAUC and f) CIAUC graphs after applying the threshold. IAUC is more Gaussian after excluding
the noise and the necrotic pixels from processing. Both necrotic and poorly vascularized parts of
the tumor can be seen in the subtracted image. The solid line represents the kidney tumors and
the dashed line represents the normal kidneys result.
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Figure 6.4: the R50 values with and without applying the threshold for a) the tumor bearing
kidneys and b) the normal kidneys. The open diamonds represent the R50 values before applying
threshold and the full diamonds represent the R50 values after applying threshold. Each point
represents the mean of the R50 values for 3 mice per group.

FAP values

Normal Kidney

Tumor Kidney

control

0.85

0.73

SU10

0.83

0.63

SU20

0.56

0.81

0.79
0.6
SU40
Table 6.1: FAP values for the normal kidney and tumor kidney (We are showing one mouse per
group).

Using the filtered DCE data, the uptake of Gd-DTPA was compared between the four
different groups (SU10, SU20, SU40 and control) by evaluating the R50 and the NR50 values.
We found that the contrast agent uptake by the tumor bearing kidney treated with a intermediate
dose of 20 mg/kg/day was higher compared to the normal kidneys in untreated mice (control) or
those treated with high and low doses of sunitinib, i.e., SU 40 and SU10 with slower kinetics of
wash out (Hillman et al., 2009). However, in these mice treated with SU20, both tumor-bearing
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kidneys and normal kidneys have similar kinetics of uptake and wash out of Gd-DTPA. This is
confirmed also from the NR50 values (Figure 6.5) (Hillman et al., 2009).

NR50 Values
0.50
0.45
0.40

NR50

0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00

control

su 10

su 20

su 40

Figure 6.5: NR50 values were calculated by normalizing the tumor-bearing kidney to the normal
kidneys. Note that treatment with SU 20mg/kg/day improved tumor perfusion with comparable
CA uptake as the normal kidneys. However, in control and mice treated by SU40 or SU10, the
tumor uptakes more CA compared to the normal kidneys (Hillman et al., 2009). The figure
shows 3 mice per group.

6.4.2 Kidney Regional Analysis
DCE parametric maps were used to evaluate the vascular kinetics of different kidney
regions. Figure 6.6 shows the middle slice of the DCE parametric maps of a normal mouse (i.e.,
has no RCC injection). DCE parametric maps were color coded in order to see variation more
easily. The two kidneys appear consistence in the parametric maps. Nevertheless, the kidneys
main regions also clearly appear. Normal kidneys have 4 main regions: the cortex, the medulla,
the calyx and the pelvis. From the DCE parametric maps, we see that the calyx-pelvis region has
high AUC, Pslope, PEAK and Nslope values indicated by the red color. AUCtp has a high values
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inside the pelvis region, which might indicate that the slice has cut the renal artery. TTP values
are shorter in the kidneys comparing to the surrounding tissues.

AUC

Pslope

AUCtp

TTP

PEAK

Nslope

Figure 6.6: the DCE parametric maps. Mouse was imaged by DCE-MRI for 30 time points at 7second intervals. Baseline images were collected for the first during 10 time points before Gd
contrast agent injection. At time point 10, Gd was injected in the tail vein, and images were
collected for 20 more time points. The DCE parametric maps are obtained from C(t) curves. The
total contrast agent uptake (AUC), rate of uptake (Pslope), peak concentration (PEAK), uptake to
the peak (AUCtp), time to peak (TTP) and the rate of Gd clearance (Nslope) in the kidney ROIs
are shown.

Figure 6.7 shows the DCE parametric maps for a control mouse. The parametric maps
succeed to differentiate the tumor core from its periphery. Tumor core (in the right kidney) has
low AUC, Pslope, PEAK and Nslope values indicated by the dark blue color in the parametric

116
maps as well as a relatively long TTP values. This suggests that the core of the tumor has poor
blood supply. On the other hand, the periphery of the tumor has a high AUC value indicating a
high blood supply. Looking at the normal kidney results, we can see that calyx-pelvis region has
a similar AUC, Pslope and PEAK values compared to the periphery of the tumor-bearing kidney
but a higher Nslope values. This might suggest that the normal kidney is functioning normally.

AUC

Pslope

AUCtp

TTP

PEAK

Nslope

Figure 6.7: DCE-MRI of KCI-18 KTs. Mouse bearing established tumors in the right kidneys
was treated every day for 7 days with vehicle only (control). Then, the mouse was imaged by
DCE-MRI for 30 time points at 7-second intervals. Baseline images were collected for the first
during 10 time points before Gd contrast agent injection. At time point 10, Gd was injected in the
tail vein, and images were collected for 20 more time points. The DCE parametric maps are
obtained from C(t) curves. The total contrast agent uptake (AUC), rate of uptake (Pslope), peak
concentration (PEAK), uptake to the peak (AUCtp), time to peak (TTP) and the rate of Gd
clearance (Nslope) in the kidney ROIs are shown.(control 164-march 2010)
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To quantify the regional response after sunitinib treatment in mice, two ROIs representing
the periphery and core of kidney tumors and two ROIs representing the cortex and medulla of
normal kidneys were drawn separately on AUC, Pslope, PEAK, AUCtp, TTP and Nslope maps
for each mouse. Each ROI was quantified and the results are shown as mean ± SD in Table 6.2.
Looking at the values from parametric quantifications of the control mice, we notice that the Gd
uptake, Pslope, PEAK, TTP, AUCtp and Nslope by the tumor periphery is higher than that value
by the normal cortex. However, the tumor core have lower Gd uptake, Pslope, PEAK, AUCtp
and Nslope values compared to the normal medulla. These finding agrees with the pathology of
RCC.
The results were compared between the four different groups (SU10, SU20, SU40 and
control). The low dose of SU10 in the kidney tumors had no effect in the core of the tumor
compared to the control mice. SU20 and SU40 treatment doses were found to enhance the blood
perfusion and clearance of the core and only SU40 dose was found to increase the Pslope, PEAK
and Nslope in the tumor periphery (see Table 6.2-a). In the normal kidneys, mice treated with
SU10 and SU20 have almost the same AUC, Pslope and PEAK compared to control mice normal
kidneys. However, increasing the treatment dose to 40 mg/kg/day affects the Gd-DTPA Pslope,
PEAK and Nslope in the cortex and the medulla of normal kidneys compared to the control mice
normal kidneys (see Table 6.2-b). These findings from Table 6.2 were confirmed by histological
observations of tissues showing that using SU40 as a treatment dose caused tumor vessel
destruction associated with hemorrhages in tumor-bearing kidneys and dilatation of blood
vessels in normal kidneys (Hillman et al., 2009). Mice treated with SU20 had more regularized
and thinner vessels in kidney tumors and mild dilatation in a few vessels in normal kidneys. In
contrast, mice treated with SU10 had enlarged abnormal vessels in tumor-bearing kidneys and
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regular vessels in normal kidneys similar to the findings from control mice (Hillman et al.,
2009).

a) Tumor Bearing Kidneys:
Parametric maps:
Region:

Periphery

Core

Control
SU10
SU20
SU40

AUC
mmol.ms
0.23±0.12
0.18±0.06
0.18±0.03
0.22±0.04

Pslope
mmol/ms
26± 3
21± 6
20 ± 2
37± 10

PEAK
10-4 mmol
7 ± 0.4
6±2
5± 0.6
9±3

TTP
ms
110±10
132±17
99±4
103±11

AUCtp
10-3 mmol.ms
25± 4
31±11
14±2
27±10

Nslope
mmol/ms
16±3
9±3
11±0.6
25±9

Control
SU10
SU20
SU40

0.06± 0.03
0.05 ± 0.02
0.10 ± 0.00
0.10± 0.02

10 ± 1
6±1
13± 6
18 ± 10

2± 0.6
2 ± 0.7
3 ± 0.8
5± 2.5

153±2
146±15
130±29
142±22

15±4
14±8
16±5
25±4

5±0.3
3±0.2
9±6
12±10

b) Normal Kidneys:
Parametric maps:
Region:
Control
SU10
SU20
SU40

0.15± 0.05
0.16± 0.08
0.17 ± 0.02
0.18 ± 0.03

Pslope
mol/ms
22 ± 0.1
18 ± 0.8
19 ± 2
33 ± 12

Control
Medulla SU10
SU20
SU40

0.17 ± 0.09
0.13 ± 0.07
0.14 ± 0.01
0.13 ± 0.01

16± 0.2
13 ± 0.8
14± 0.3
20 ± 6

Cortex

AUC mmol.ms

PEAK
10-3 mmol
5 ± 0.2
4 ± 0.4
4 ± 0.5
7±3

TTP
ms
99±4
112±14
100±3
94±6

5± 0.3
3 ± 0.5
4 ± 0.3
5±1

122±17
131±13
108±8
102±3

AUCtp
Nslope
10 mmol.ms mmol/ms
17±3
14±0.1
18±6
9±1
14±1
11±2
19±8
20±11
-3

23±7
21± 8
15±3
16±3

11±3
7±1
10±2
13±3

Table 6.2: DCE characteristic table. a) two ROIs representing the periphery and core of kidney
tumors and b) two ROIs representing the cortex and medulla of normal kidneys were drawn,
separately, on AUC, Pslope, PEAK, AUCtp, TTP and Nslope maps for each mouse. Each ROI
was quantified and the results are shown as mean ± SD.
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Blood Volume Fraction (λ)
For some cases the renal artery was clearly seen in the DCE images. These case where
used to evaluate the blood volume fraction (λ). The result showed an increase of the blood
volume fraction for the control kidney tumor compared to the normal kidney. However, for mice
treated with dose of 20 mg/kg/day and 10 mg/kg/day the blood volume fraction of both kidneys
appear to be the same (see Table 6.3). Interestingly, for the mouse treated with SU 40, we
noticed a dramatical increase in the blood volume fraction for both normal and tumor-bearing
kidneys (see Table 6.3).

λ values

Tumor Kidney

Normal Kidney

control

0.80

0.50

SU10

0.52

0.49

SU20

0.57

0.59

0.98
0.94
SU40
Table 6.3: blood volume fraction (λ) values for the normal kidney and kidney tumor. The table
show the result for one mouse per group where the renal artery where clear.

6.4.3 Full Width at the Half Maximum (FWHM)
We found that the tumor-bearing kidneys in control, SU40 and SU10 treated mice had a
very broad IAUC as indicated by the FWHM values; it exceeds 2 mmol.sec (Figure 6.8-a). For
normal kidneys, FWHM ranges between 1.5 and 2 mmol.sec for all mice groups except the SU40
treated group (Figure 6.8-b). Increasing the sunitinib treatment dosage to 40 mg/kg/day, both
normal and tumor-bearing kidneys have higher FWHM values. This might be explained by the
increased permeability and poor clearance of the blood vessels in the tumor bearing kidneys
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compared to the control normal kidneys or other treated normal kidneys with dosages of 10 and
20 mg/kg/day of sunitinib. With SU20 mg/kg/day, the FWHM became narrower and behaved
more like normal kidneys in both control and SU10-treated mice (Figure 6.8-a & 6.8-b).

FWHM-Tumor Kidney

b

FWHM-Normal Kidney

3

2.5

2.5

2

2

FWHM

FWHM

a3
1.5
1

1.5
1

0.5

0.5

0

0

control

su 10

su 20

su 40

control

su 10

su 20

su 40

Figure 6.8: FWHM results. FWHM values for a) tumor-bearing kidneys and b) normal kidneys.
Notice that higher FWHM values for control, SU40 and SU10 mice compared to the SU20 mice
in kidney tumors. In normal kidneys FWHM almost stayed at the same range between different
groups of treatment.
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6.5 Discussion
Dynamic MRI scans with injection of GD-DTPA are considered to be a robust method
used to study diseases that alter blood perfusion and tissue micro-vascular parameters of human
tissue. However, tumor heterogeneity is one of the factors that lead to DCE results variation from
center to another. The presence of necrotic cells in the tumor-bearing kidneys greatly affects the
R50 values and shifts the CIAUC curves more to the left compared to the R50 values after
applying the threshold as seen in Figure 5.3-d and Figure 5.3-f. The combined use of
thresholding both the original DCE data and subtracted data proved to be a useful tool to
differentiate between noise thresholded pixels from necrotic thresholded pixels. However, the
noise in the subtracted images can be lowered by averaging the images acquired before Gd
injection and subtracted it from a set of images after Gd injection instead of taking only one time
point set of images and subtracted it from a set of images after Gd injection. FAP provided a new
parameter to quantify the effect of sunitinib treatment on RCC tumors. Cases with high FAP for
the normal kidneys will be more trusted than cases with low FAP. Higher FAP in the normal
kidneys’ region indicates that more pixels will be considered as active pixels and included in
further analysis and less noisy pixels will be excluded. Hence, FAP of the tumor ROI will give
an indication of the necrotic part percentage of the tumor compared to its active part. After drug
treatment, the vessels may be affected in a way that changes the tissue which took up Gd and
hence affect FAP values. Therefore, FAP measurement is expected to give an indication of drug
effects on the tumor, where lower FAP indicates a more necrotic and less active tumor and a
higher FAP, closer to 1, indicates a high percentage of active tumor cells compared to necrotic
cells inside the ROI.
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The newly developed DCE parametric maps are used to study the effect of sunitinib
treatment on the main regions of the kidney. The main function of the kidney is to maintain
homeostasis or equilibrium between internal volume and electrolyte status and that of
environmental influence, diet and intake. It has two main regions: the cortex and the medulla that
function to maintain the intra and extracellular fluid status at a constant rate despite the wide
variety of daily fluid and electrolyte intake. Understanding the antiangiogenic treatment effects on
kidney tissue might further help to better schedule treatment or better propose new treatment
combinations.

Our result on the pre-clinical RCC tumor model demonstrates that DCE

parametric maps have the potential to assess the effect of antiangiogenic drugs on blood flow and
vascular changes in tumors as well as in normal tissues by creating a characteristic table that
describes the contrast agent uptake and the washout behavior of the tumor and normal tissue.
From quantifying the DCE parametric maps, we noticed that SU40 had a dramatic effect on
Pslope and Nslope values in both the cortex and medulla of normal kidneys compared to those
values for normal kidneys in control mice. These results indicate that this high dose causes
significant vascular damage. On the other hand, the SU20 data from tumor-bearing kidney
showed results similar to that of a healthy normal kidney, where both Pslope and Nslope values
of tumor periphery and core return to similar values as seen for the cortex and medulla of the
normal kidneys in control mice. Looking at results from normal kidneys treated with SU20, we
see almost no effect on the Pslope and Nslope values compared to the control mice values,
indicating that this dose may be safer and regularizes the tumor vessels. We also noticed that
SU40 has a greater effect on the cortex compared to the medulla of normal kidneys; this agrees
with the fact there is a higher blood supply in the kidney cortex compared to the medulla.
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Interestingly, from SU20 data, the AUCtp value of the tumor periphery is back in the
range of AUCtp values for normal kidneys of all mice, but still lower in the tumor core. This
might present more proof supporting the hypothesis that blood vessels trim the use of SU20 as a
treatment dose. For control, SU10 and SU40 AUCtp values are high in the tumor periphery
which agrees again with the histological finding of highly vascularized areas in control and SU10
treated mice and hemorrhage in SU40 treated mice (Hillman et al., 2009).
As we showed earlier, FWHM values for the mice treated with SU20 return to the normal
range; this agrees with the histology result and supports our hypothesis regarding vessel
trimming as has been shown in our previously published results (Hillman et al., 2009). FWHM
measures of the IAUC curves may prove to be a useful indirect measure of vessel leakiness
where it appears to be related to Gd uptake and washout (i.e., Pslope and Nslope) inside the ROI.
FWHM studies the effects of drug treatment over all active pixels in the selected ROI and not
only one pixel.
The new DCE parameters introduced here (i.e., FAP, AUCtp, Nslope and FWHM)
provides further guidance as to what could be considered normal versus abnormal tissue
response to antiangiogenic therapy. These measures are expected to help in understanding
treatment effects throughout the kidney which might help anticipate problems that patients might
develop after treatment and try to provide them with a suitable solution. Regional analysis using
DCE parametric maps has the potential to decrease the effect of tumor heterogeneity on DCE
results and hence, enhances DCE reproducibility. Another advantage for DCE parametric maps
over DCE model free analysis is that model free analyses are time dependant and the results will
depend on the number of the time points included for further analysis. Moreover, in model free
analysis, fixed number of time points is included for processing for all the cases which might
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lead to lose each case privacy especially in very functionally important areas such as the kidneys.
On the other hand, the measurements derived from the DCE parametric maps can quantify the
physiological vascular changes in tissue are independent from integration time points. We think
that regional analysis using DCE parametric maps should be considered by other centers when
testing new antiangiogenic drugs.
Estimating the blood volume fraction (λ) from the AUCtp map can be considered as a step
closer to a dynamic susceptibility contrast (DSC) like analysis of tissue permeability like
properties.
In conclusion, this newly introduced DCE characteristic table has the potential to
quantify the effect of antiangiogenic drug treatment, such as sunitinib, throughout the region of
interest and should lead to a clear improvement in the ability of DCE-MRI as a quantifying
method to study the tumor vasculature and other hemodynamic properties.
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Chapter Seven
Conclusion and Future Directions:

Magnetic resonance imaging with an injection of gadolinium chelates is considered to be
the most robust method used to study diseases that affect blood perfusion and tissue microvascular parameters of human tissue. Observation of contrast enhancement is typically achieved
using a dynamic imaging technique where a contrast agent is injected during the acquisition of a
dynamic image set and can give quantitative information about tissue hemodynamic parameters
such as blood volume, blood flow and tissue permeability.
The new algorithm we introduced in this project is to use a fixed T1(0) value. This
approach will provide us with more reproducible DCE results. This algorithm has also enhanced
the ability of DCE-MRI as a tool to be able to decide the best treatment dose among a number of
different doses of the antiangiogenic drug, sunitinb, which can be mistakenly used in a high dose
for tumor treatment and can harm normal healthy tissues. Also in this project we introduced a
number of new parameters including fraction of active pixels (FAP), contrast agent uptake to the
peak (AUCtp), time to peak concentration (TTP), washout slope (Nslope) and full width half
maximum (FWHM). These new parameters are independent of the integration time points but on
the other hand can be used to estimate Toft’s parameters, such as Ktrans and Kep when AIF is not
available.
Scheduling for cancer treatment is one of the important tasks oncologists face.
Understanding effects of antiangiogenic drugs on the tumor vasculature can help in better
planning for treatment regimens. In chapter two, we discussed the tumor angiogenesis process
where abnormal blood vessels start proliferation. These blood vessels are leaky and enlarged
compared to normal blood vessels. The defects in tumor blood vessels might lead to
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elevated interstitial tissue pressure; impaired blood supply; and decreased oxygen supply, in the
tumors. These factors could lead to a decrease of the efficacy chemotherapy and radiotherapy.
As we investigated in chapter four, DCE-MRI succeeded in determining the best
treatment dose for RCC tumors with less impact on healthy kidney tissues. These results opened
new avenues for further investigations with the pre-selected sunitinb dose (i.e., 20 mg/kg/day)
combined with other cytotoxic drugs and/or radiotherapy. From our study we found that DCE
was a reliable tool to monitor vascular changes induced by various doses of suntinib in kidney
tumors as well as in normal kidney tissue. We showed that a treatment of a daily sunitinb dose of
20

mg/kg/day mildly affected

the

normal vessels but

caused

better

tumor

perfusion

of contrast agent and decreased vascular permeability in agreement with histological
observations of the thinning and regularization of tumor vessels.
We have established the conditions for the combination of antiangiogenic therapy with
sunitinib and cytoxic therapy with gemcitabine (a chemotherapy drug) that result in significant
long-lasting anti-tumor response. We also used the idea of blood vessel normalization that is,
using the antiangiogenic drug, sunitinb, and combining it with radiotherapy; we hypothesize that
blood vessels trimming can enhance oxygen delivery to the tumor and hence enhance the
radiotherapy treatment results (work under progress).
Moreover, our future directions are to use these DCE-parametric maps (i.e, Pslope, Peak,
TTP, AUCtp and FWHM) as a different mean to represent the usual Ktrans and Kep values that is
extracted from Toft’s Model using a special Taylor series expansion approach. This will be very
beneficial when AIF information is not available.
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In conclusion, the results of this research should lead to a clear improvement in the ability
of MRI as a quantifying method to quantify tumor vasculature and other hemodynamic
properties.
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ABSTRACT

QUANTIFICATION OF VASCULAR PARAMETRIC INDICES USING DYNAMIC
CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING
by
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Degree: Doctor of Philosophy
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive method used to evaluate the biological activity in early clinical trials of novel drugs
targeting the tumor vasculature using gadolinium-DTPA (Gd) as a contrast agent. However, it
has some limitations, such as reproducibility, data acquisition times, the presence of noise,
extracting contrast concentration, estimating T1 relaxation and estimating pharmacokinetic
parameters.
In this work, a new approach to used fixed T1(0) which provides more reproducible
DCE results has been introduced. Using this new algorithm to quantify the vascular changes in
DCE-MRI, a pre-clinical renal cell carcinoma (RCC) tumor model was used to demonstrate the
ability of DCE-MRI to quantify the vascular changes induced by various doses of sunitinib in
tumor-bearing kidneys and normal contralateral kidneys. Usually, only the first minute of data
are used for processing to calculate the initial area under the curve (IAUC) and/or the median
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value of cumulative initial area under the curve (CIAUC) in order to monitor changes between
pre and post drug treatment. However, in this work, the first two minutes was used to include the
effect of the washout process of the kidneys. Moreover, DCE-MRI was used to investigate the
vascular changes induced by pre-treatment with sunitinib in KCL-18 kidney tumors to
schedule the initiation of chemotherapy. DCE results were confirmed with the histologic studies.
In this thesis, several new measures of vascular properties have been introduced,
including: the fraction of active pixels (FAP); contrast agent uptake to the peak (AUCtp); time
to peak concentration (TTP); washout slope (Nslope); as well as full width half maximum
(FWHM) of IAUC. The results from the pre-clinical RCC tumor model demonstrate that DCE
parametric maps have the potential to assess the effect of antiangiogenic drugs on blood flow and
physiological vascular changes in tumors as well as normal tissues. These new parametric maps
provided further guidance as to what could be considered normal versus abnormal tissue
response to antiangiogenic therapy. The results of this research should lead to a clear
improvement in the ability of DCE-MRI as a quantitative method to evaluate tumor vasculature
and other hemodynamic properties.
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